<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Uncommon congenital adrenal hyperplasias</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Uncommon congenital adrenal hyperplasias</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Uncommon congenital adrenal hyperplasias</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard J Auchus, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lynnette K Nieman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katya Rubinow, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 28, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H93045339"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Congenital adrenal hyperplasia (CAH) refers to several disorders characterized by genetic defects in the proteins and enzymes involved in cortisol biosynthesis  (<a class="graphic graphic_figure graphicRef71558" href="/d/graphic/71558.html" rel="external">figure 1</a>). The decrease in cortisol production releases the feedback inhibition of cortisol on the pituitary and increases the production of corticotropin (ACTH). High ACTH causes adrenal hyperplasia and drives excessive accumulation of cortisol precursors and/or overproduction of ACTH-dependent adrenal steroids along other pathways. The clinical manifestations of the different disorders are due to diminished production of cortisol and, depending upon the site of block, decreased or increased production of mineralocorticoids and/or androgens. (See  <a class="medical medical_review" href="/d/html/120.html" rel="external">"Adrenal steroid biosynthesis"</a>.)</p><p>Treatment aims to replace steroid deficiencies and reduce the production or block the action of steroid excess. The most common cause of CAH worldwide, accounting for &gt;90 percent of cases, is 21-hydroxylase deficiency (21OHD) [<a href="#rid1">1</a>]. The prevalence of other forms of CAH varies geographically, largely due to founder mutations that are often isolated in specific regions. All forms of CAH are inherited as autosomal recessive traits. This topic review will discuss the clinical and biochemical characteristics of the other forms of CAH, including:</p><p class="bulletIndent1"><span class="glyph">●</span>CYP17A1 deficiencies (combined 17-hydroxylase/17,20-lyase deficiency [17OHD] and isolated 17,20-lyase deficiency [ILD]). (See <a class="local">'CYP17A1 deficiencies'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>3-beta-hydroxysteroid dehydrogenase type 2 deficiency. (See <a class="local">'3-beta-hydroxysteroid dehydrogenase type 2 deficiency'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CYP11B1 deficiency (11-hydroxylase deficiency [11OHD]). (See <a class="local">'11-beta-hydroxylase deficiency'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cytochrome P450-oxidoreductase (POR) deficiency (ORD). (See <a class="local">'P450 oxidoreductase deficiency (apparent combined CYP17A1 and CYP21A2 deficiency)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hexose-6-phosphate-dehydrogenase deficiency (apparent cortisone reductase deficiency [ACRD]). (See <a class="local">'Hexose-6-phosphate-dehydrogenase deficiency (apparent cortisone reductase deficiency)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Phosphoadenosine phosphosulfate synthase type 2 (PAPSS2) deficiency (apparent dehydroepiandrosterone [DHEA] sulfotransferase deficiency). (See <a class="local">'PAPSS2 deficiency (apparent DHEA sulfotransferase deficiency)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lipoid congenital adrenal hyperplasia (LCAH). (See <a class="local">'Lipoid congenital adrenal hyperplasia'</a> below.)</p><p></p><p>ACRD and PAPSS2 deficiency are not strictly CAH disorders, since these conditions lack cortisol deficiency. In the lipoid CAH diseases, production of all steroids is low.</p><p class="headingAnchor" id="H1698113"><span class="h1">CYP17A1 DEFICIENCIES</span><span class="headingEndMark"> — </span>The cytochrome P450 17A1 enzyme (CYP17A1) catalyzes both the 17-hydroxylase reaction, which forms 17-hydroxysteroids, and the 17,20-lyase reaction, which cleaves 21-carbon 17-hydroxysteroids to 19-carbon 17-keto androgen precursors  (<a class="graphic graphic_figure graphicRef52616" href="/d/graphic/52616.html" rel="external">figure 2</a>) [<a href="#rid2">2</a>]. Most defects in CYP17A1 impair both enzymatic activities and cause combined 17-hydroxylase/17,20-lyase deficiency (17OHD), which can be complete or partial [<a href="#rid3">3</a>]. The prevalence appears to be highest in Brazil [<a href="#rid4">4,5</a>]. Isolated 17,20-lyase deficiency (ILD) is extremely rare [<a href="#rid6">6,7</a>], with only approximately six cases described.</p><p>CYP17A1 is expressed both in the human adrenal and gonads [<a href="#rid8">8</a>], and thus, these deficiencies are forms of CAH that impair both adrenal and gonadal function. ILD, in contrast, does not significantly lead to adrenal hyperplasia and is more a form of gonadal insufficiency.</p><p class="headingAnchor" id="H1698120"><span class="h2">Pathophysiology</span><span class="headingEndMark"> — </span>The hallmarks of 17OHD, first described in 1966 [<a href="#rid3">3</a>], include hypertension and hypokalemia due to the accumulation of cortisol precursors with mineralocorticoid activity upstream of the block, plus sexual infantilism due to inability to synthesize androgens and estrogens. Unlike most other forms of CAH, mineralocorticoid excess and high corticosterone production [<a href="#rid9">9</a>] mitigate the clinical consequences of cortisol deficiency, and symptomatic adrenal insufficiency is rare [<a href="#rid4">4,10-16</a>].</p><p>CYP17A1 metabolizes pregnenolone, progesterone, and their 17-hydroxy derivatives early in the steroidogenic cascades  (<a class="graphic graphic_figure graphicRef52616" href="/d/graphic/52616.html" rel="external">figure 2</a>) [<a href="#rid11">11</a>]. Consequently, 17OHD eliminates the synthesis of most steroids and limits steroidogenesis to progesterone, 11-deoxycorticosterone (DOC), corticosterone, and 18-oxygenated derivatives  (<a class="graphic graphic_table graphicRef104126" href="/d/graphic/104126.html" rel="external">table 1</a>) [<a href="#rid12">12,13</a>]. DOC binds with high affinity to the mineralocorticoid receptor and is not a substrate for 11-beta-hydroxysteroid dehydrogenase type 2. DOC excess causes volume expansion, hypertension, and kaluresis despite suppressed renin and aldosterone production.</p><p>The lack of 17,20-lyase activity precludes conversion of 21-carbon steroids to 19-carbon androgen precursors in both 17OHD and ILD  (<a class="graphic graphic_figure graphicRef52616" href="/d/graphic/52616.html" rel="external">figure 2</a>). In ILD, 17-hydroxylation is largely preserved, and DOC and corticosterone accumulation are limited; hence, hypertension and hypokalemia as clinical manifestations of 17OHD are not found. Low 19-carbon steroid production, however, causes variable degrees of genital atypia in affected 46,XY males with a tendency for gynecomastia during puberty, as occurs in many states of low <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> synthesis. Affected girls develop only sparse pubic hair and can have dysmenorrhea [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H520889525"><span class="h2">Clinical presentation</span><span class="headingEndMark"> — </span>The classic presentation of <strong>severe</strong> 17OHD in phenotypic females (who can have 46,XX or 46,XY karyotype) includes [<a href="#rid3">3,9,10,17</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension</p><p class="bulletIndent1"><span class="glyph">●</span>Primary amenorrhea</p><p class="bulletIndent1"><span class="glyph">●</span>Absence of secondary sexual characteristics</p><p class="bulletIndent1"><span class="glyph">●</span>Minimal body hair </p><p class="bulletIndent1"><span class="glyph">●</span>Blind vaginal pouch similar to androgen insensitivity syndrome (46,XY only)</p><p class="bulletIndent1"><span class="glyph">●</span>Small uterus and ovaries that may develop large cysts in adolescence due to high gonadotropins and progesterone (46,XX only)</p><p></p><p>The hypertension, which is typically detected in early adulthood [<a href="#rid18">18</a>], may be present much earlier [<a href="#rid19">19</a>] and can be severe [<a href="#rid20">20</a>] but may be normalized with treatment [<a href="#rid21">21</a>]. (See <a class="local">'Treatment'</a> below.)</p><p>In <strong>partial</strong> forms of 17OHD, 46,XY patients are often identified in infancy due to atypical genitalia with intraabdominal or inguinal testes. Since estrogens derive from androgens, estrogen synthesis is secondarily impaired, but since estradiol is an extremely potent inducer of breast development, particularly when androgens are low, some breast development may be seen. Biochemical evidence of a partial hydroxylation defect may be observed without clinical manifestations of hypertension or hypokalemia [<a href="#rid22">22</a>].</p><p>ILD is generally diagnosed in males with undervirilization, gynecomastia, and failure to develop secondary sexual characteristics due to the testicular enzyme deficiency [<a href="#rid6">6,7</a>]. Females with ILD have been identified in families with affected males; they present with delayed pubarche and oligomenorrhea [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H520889511"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of 17OHD is established by demonstrating an elevated precursor-to-product ratio in serum at baseline or under cosyntropin stimulation [<a href="#rid4">4</a>]. In general, the diagnosis is established by showing elevated DOC (&gt;100 ng/dL [&gt;3 nmol/L]) and corticosterone (&gt;4000 ng/dL [&gt;116 nmol/L]) with low cortisol (&lt;5 mcg/dL [&lt;138 nmol/L]), androgens, and estrogens. Progesterone is also elevated [<a href="#rid23">23</a>], while aldosterone and renin are suppressed  (<a class="graphic graphic_table graphicRef104126" href="/d/graphic/104126.html" rel="external">table 1</a>). Gonadotropins and corticotropin (ACTH) are elevated even in children.</p><p>The characteristic feature of ILD is the elevated 17-hydroxyprogesterone (17OHP)/androstenedione ratio (&gt;50) [<a href="#rid6">6</a>], with all downstream (19-carbon) steroids reduced and 17-hydroxysteroids at or near normal.</p><p class="headingAnchor" id="H520889518"><span class="h3">Differential diagnosis</span><span class="headingEndMark"> — </span>The differential diagnosis of ACTH-dependent mineralocorticoid excess is shown in the table  (<a class="graphic graphic_table graphicRef104126" href="/d/graphic/104126.html" rel="external">table 1</a>). Most of these other conditions are distinguished from 17OHD in that DOC is not elevated, and 11-beta-hydroxylase deficiency (11OHD) is distinguished by the presence of high androgens as opposed to low androgens in 17OHD. (See <a class="local">'11-beta-hydroxylase deficiency'</a> below.)</p><p>The differential diagnosis of undervirilization in males is one of the most difficult in pediatric endocrinology and is discussed separately. (See  <a class="medical medical_review" href="/d/html/7471.html" rel="external">"Diagnosis and treatment of disorders of the androgen receptor", section on 'Diagnosis'</a>.)</p><p>P450 oxidoreductase (POR) deficiency (ORD) [<a href="#rid24">24</a>] can be difficult to distinguish from 17OHD and ILD [<a href="#rid25">25</a>] clinically and biochemically  (<a class="graphic graphic_figure graphicRef53155" href="/d/graphic/53155.html" rel="external">figure 3</a>) (see <a class="local">'P450 oxidoreductase deficiency (apparent combined CYP17A1 and CYP21A2 deficiency)'</a> below). Urinary steroid profiling by gas chromatography-mass spectrometry (GC-MS) and molecular diagnostics are extremely useful methods for confirming the diagnosis [<a href="#rid26">26,27</a>] but are not routinely available. In 17OHD, metabolites of DOC and corticosterone are elevated, while 17OHP and 19-carbon steroid metabolites are low; in ORD, metabolites of both 17OHP and corticosterone are characteristically elevated due to combined 21- and 17-hydroxylation defects, and 19-carbon steroids are also reduced. Progesterone is elevated in both conditions.</p><p class="headingAnchor" id="H1698127"><span class="h2">Genetics</span><span class="headingEndMark"> — </span>As expected with an autosomal recessive inheritance, some patients were offspring of consanguineous marriages, and obligate heterozygotes have mild defects in 17-hydroxylation, which can be revealed by ACTH stimulation [<a href="#rid28">28-30</a>].</p><p>Approximately 100 different mutations in the <em>CYP17A1</em> gene, which is located on chromosome 10q24.3 [<a href="#rid31">31</a>], have been defined [<a href="#rid2">2,15</a>].</p><p>Mutations causing 17OHD map to all regions of the protein and are predicted to impair substrate binding, heme incorporation, and protein folding [<a href="#rid7">7,25,32-45</a>].<strong> </strong>In Brazil, the founder mutations R362C and W406R account for &gt;80 percent of affected alleles and, in part, explain the unusually high prevalence of the disease in this country, with only half of patients from consanguineous families [<a href="#rid5">5</a>]. New mutations continue to be identified in all regions of the gene [<a href="#rid46">46-49</a>], and recurring mutations include F53 deletion, R96W or Q, R239Q or X, Y329D or X or ins/del, H373D or N or L, P406R, a CATC duplication at I479, D487-F489 deletion, and D487-S488 duplication [<a href="#rid15">15</a>].</p><p>In general, the severity of the clinical phenotype correlates with the degree of impairment of enzymatic activity demonstrated in heterologous assay systems [<a href="#rid11">11,39,50,51</a>]. However, these assays do not explain occasional differences in clinical presentation despite the same <em>CYP17A1</em> genotype. In vitro assays with mutations causing ILD convincingly demonstrate very low, but not absent, 17,20-lyase activity, despite preferentially preserved 17-hydroxylase activity [<a href="#rid52">52</a>].</p><p class="headingAnchor" id="H1698134"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>The goals of treatment in classic 17OHD are to mitigate the effects of mineralocorticoid excess, prevent glucocorticoid deficiency, and restore desired secondary sexual characteristics with attendant benefits such as improved bone mineral density (BMD). This can be achieved by mineralocorticoid blockade and physiologic replacement doses of cortisol and sex steroids, rather than by supraphysiologic suppressive doses of glucocorticoid as have been used in the past.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucocorticoid replacement</strong> – Patients with glucocorticoid deficiency require physiologic cortisol replacement therapy. Cortisol replacement regimens for children and adults are reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/5825.html" rel="external">"Treatment of adrenal insufficiency in children", section on 'Glucocorticoids'</a> and  <a class="medical medical_review" href="/d/html/155.html" rel="external">"Treatment of adrenal insufficiency in adults", section on 'Glucocorticoid replacement for all patients'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mineralocorticoid blockade</strong> – For patients reared as female, <a class="drug drug_general" data-topicid="9943" href="/d/drug information/9943.html" rel="external">spironolactone</a> is the drug of choice to block the mineralocorticoid receptor. Medications are titrated based on monitoring blood pressure, DOC, corticosterone, and electrolytes; renin suppression can persist for years, despite adequate therapy, in some cases [<a href="#rid12">12,53</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sex steroid replacement and fertility</strong> – Sex steroid treatment regimens vary with physiologic stage and goals of therapy. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Puberty induction</strong> – Puberty is induced with low-dose estrogen at the expected time of pubarche. Cyclical withdrawal bleeding is only required for 46,XX females with an intact uterus. Androgen replacement has not been studied in this disorder. (See  <a class="medical medical_review" href="/d/html/5814.html" rel="external">"Approach to the patient with delayed puberty", section on 'Estradiol therapy'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fertility</strong> – A few cases of in vitro fertilization and a live birth in a 46,XX patient with incomplete 17OHD have been described [<a href="#rid54">54</a>]. The approach included ovulation induction with gonadotropin stimulation, egg retrieval, and freezing of embryos. During the ovarian stimulation with gonadotropin-releasing hormone (GnRH) agonist and recombinant follicle-stimulating hormone (rFSH) administration, adrenal-derived progesterone secretion was suppressed with <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a>. Estradiol valerate was then given to prepare the endometrium, and the frozen-thawed embryo transfer was performed.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treatment of atypical genitalia</strong> – Treatment for 46,XY patients with a difference of sex development (DSD) due to ILD and partial 17OHD is much more complex and incorporates attention to genital surgery for hypospadias or clitoral reduction for those being reared as females. <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">Testosterone</a> replacement may be given to stimulate penile growth in childhood and then resumed in adolescence and adulthood. (See  <a class="medical medical_review" href="/d/html/5807.html" rel="external">"Management of the infant with atypical genital appearance (difference of sex development)", section on 'Long-term management'</a>.)</p><p></p><p class="headingAnchor" id="H159859022"><span class="h1">3-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2 DEFICIENCY</span><span class="headingEndMark"> — </span>3-beta-hydroxysteroid dehydrogenase type 2 (HSD3B2) deficiency is a rare form of congenital adrenal hyperplasia (CAH) in which synthesis of all active steroid hormones is impaired. This very rare disorder, like combined 17-hydroxylase/17,20-lyase deficiency (17OHD), impairs both adrenal and gonadal steroid production [<a href="#rid55">55</a>]. Paradoxically, both male and female infants are born with atypical genitalia for reasons explained below. Mutations throughout the <em>HSD3B2</em> gene have been identified, with a few founder mutations in isolated populations [<a href="#rid56">56-68</a>].</p><p class="headingAnchor" id="H159859042"><span class="h2">Pathophysiology</span><span class="headingEndMark"> — </span>HSD3B2 catalyzes the reactions that establish the 3-keto-delta-4 A-ring structure found in the major endogenous progestins, mineralocorticoids, glucocorticoids, and androgens, including the precursors of dihydrotestosterone. Consequently, all are deficient, and since androgens are precursors to estrogens, estrogen biosynthesis is also impaired  (<a class="graphic graphic_figure graphicRef74160" href="/d/graphic/74160.html" rel="external">figure 4</a>) [<a href="#rid55">55</a>]. The resulting corticotropin (ACTH) excess drives the production of the 3-beta-hydroxy-delta-5-steroids pregnenolone, 17-hydroxypregnenolone, and dehydroepiandrosterone (DHEA), as well as their sulfates  (<a class="graphic graphic_figure graphicRef74160" href="/d/graphic/74160.html" rel="external">figure 4</a>). Unlike 17OHD, the accumulating precursor steroids do not compensate for cortisol deficiency, and newborns suffer from hypotension and hyperkalemia as in 21-hydroxylase deficiency (21OHD).</p><p>The formation of active androgens in girls occurs because a second enzyme, HSD3B1, is abundant in liver and skin [<a href="#rid57">57</a>], and this enzyme converts circulating DHEA to androstenedione. The markedly elevated output of precursor steroids leads to relatively high amounts of <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> in girls but fails to compensate fully for the defect in testicular testosterone synthesis in boys [<a href="#rid69">69</a>]. In contrast to 21OHD, 11-oxygenated androgens are relatively low, especially 11-ketotestosterone [<a href="#rid70">70</a>].</p><p>A "nonclassic" form of HSD3B2 deficiency that causes hirsutism, menstrual irregularity, or both in adolescent or young adult women was previously suggested [<a href="#rid71">71</a>], based on exaggerated serum delta-5 steroid production after cosyntropin stimulation. However, most of these patients do not have genetic HSD3B2 deficiency, but rather a form of polycystic ovary syndrome (PCOS), as the <em>HSD3B2</em> gene is normal [<a href="#rid58">58,59,72,73</a>]. True nonclassic HSD3B2 deficiency is very rare, and patients should <strong>not</strong> be given this diagnosis unless 17-hydroxypregnenolone elevation is &gt;10 standard deviations (SDs) above the normal mean (ie, &gt;5000 ng/dL or 150 nmol/L) [<a href="#rid56">56,58</a>].</p><p class="headingAnchor" id="H159859254"><span class="h2">Clinical and biochemical features</span><span class="headingEndMark"> — </span>Much like 21OHD, most patients present as neonates or in early infancy with clinical manifestations of both cortisol and aldosterone deficiency, with feeding difficulties, vomiting, volume depletion, hyponatremia, and hyperkalemia [<a href="#rid55">55,60</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">Testosterone</a> deficiency results in atypical genitalia in 46,XY newborns and persists throughout adulthood. Newborn males are undervirilized in proportion to the severity of the enzymatic deficiency, but this disease is a rarely found in boys with idiopathic hypospadias. In one study, only 2 of 90 boys with hypospadias had evidence of subtle molecular abnormalities in the <em>HSD3B2</em> gene [<a href="#rid74">74</a>].</p><p></p><p class="bulletIndent1">Newborn females often have mild virilization due to peripheral conversion of adrenal-derived DHEA to <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> by the type 1 enzyme. Females are born with mild-to-moderate clitoromegaly but little labioscrotal fusion (Prader scores II to III)  (<a class="graphic graphic_figure graphicRef52525" href="/d/graphic/52525.html" rel="external">figure 5</a>), suggesting androgen excess late in gestation [<a href="#rid56">56</a>]. Undiagnosed girls proceed to develop androgen excess, including precocious pubarche, acne, and hirsutism with menstrual disturbances. Unlike 21OHD, this disease is not specifically targeted in neonatal screening programs, and rare girls may have severe deficiency but few symptoms and escape diagnosis until they are evaluated for delayed puberty [<a href="#rid75">75,76</a>]. Premature pubarche with exaggerated serum 17-hydroxypregnenolone responses to ACTH has been described in three girls with missense mutations of the gene [<a href="#rid77">77</a>].</p><p></p><p class="bulletIndent1">The apparent paradox of androgen deficiency in males and androgen excess in girls is possible because the concentrations of androgens necessary to cause mild clitoral enlargement, hirsutism, and acne in girls (total <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> approximately 200 ng/dL [7 nmol/L]) are well below normal for a fetal or adult male (approximately 500 ng/dL [17 nmol/L]).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Biochemical features</strong> – The primary biochemical abnormalities are greatly increased ratios of delta-5 to delta-4 steroids in serum (best obtained after cosyntropin stimulation) or in urine, such as a high ratio of 17-hydroxypregnenolone (delta-5) to 17-hydroxyprogesterone (17OHP, delta-4) in serum  (<a class="graphic graphic_figure graphicRef74160" href="/d/graphic/74160.html" rel="external">figure 4</a>). As described above, serum delta-5 steroid concentrations are extremely elevated, whereas the corresponding delta-4 steroids are also elevated but not to the same degree, still yielding a high ratio. An important corollary to this pattern is that 17OHP is elevated in all androgen-excess forms of classic or nonclassic CAH (21OHD, 11-hydroxylase deficiency [11OHD], and HSD3B2 deficiency), and the latter two diagnoses should only be considered in children and women when the 17OHP is elevated and 21OHD has been excluded, including false-positive 17OHP elevation in newborn screening for 21OHD.</p><p></p><p class="bulletIndent1">The markedly increased delta-5 steroids distinguish this condition from the other diseases in the differential diagnosis, which include 11-beta-hydroxylase deficiency (11OHD), 21OHD, and ORD. (See <a class="local">'11-beta-hydroxylase deficiency'</a> below and  <a class="medical medical_review" href="/d/html/145.html" rel="external">"Clinical manifestations and diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children"</a> and <a class="local">'P450 oxidoreductase deficiency (apparent combined CYP17A1 and CYP21A2 deficiency)'</a> below.)</p><p></p><p class="bulletIndent1">Heterozygous carriers cannot be distinguished from noncarriers based on steroid measurements, even after cosyntropin stimulation [<a href="#rid73">73</a>].</p><p></p><p class="headingAnchor" id="H159859386"><span class="h2">Hormonal criteria for diagnosis</span><span class="headingEndMark"> — </span>Conclusive hormonal criteria for the diagnosis of HSD3B2 deficiency have been derived from a study of 55 adolescent and adult patients whose clinical presentation suggested HSD3B2 deficiency [<a href="#rid58">58</a>]. Of these 55, eight were homozygous for deleterious <em>HSD3B2</em> mutations, and the other 47 carried normal <em>HSD3B2</em> genes. Genotypically normal women had cosyntropin-stimulated serum delta-5-pregnenolone concentrations as high as 5000 ng/dL (150 nmol/L). The minimum serum concentrations of delta-5-17-hydroxypregnenolone in patients with genetically proven HSD3B2 deficiency derived from this study vary with age:</p><p class="bulletIndent1"><span class="glyph">●</span>Neonates ≥12,600 ng/dL (378 nmol/L)</p><p class="bulletIndent1"><span class="glyph">●</span>Tanner stage I children ≥5490 ng/dL (165 nmol/L)</p><p class="bulletIndent1"><span class="glyph">●</span>Children with premature pubarche ≥9790 ng/dL (294 nmol/L)</p><p class="bulletIndent1"><span class="glyph">●</span>Adults ≥9620 ng/dL (289 nmol/L)</p><p></p><p>These approximate values have been corroborated in another series [<a href="#rid59">59</a>], such that only stimulated delta-5-17-hydroxypregnenolone values &gt;5000 ng/dL (150 nmol/L) or more should be considered consistent with the diagnosis.</p><p class="headingAnchor" id="H159859660"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>Similar to treatment of 17OHD, therapy must include replacement of both adrenal and gonadal steroid deficiencies. (See <a class="local">'CYP17A1 deficiencies'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span>In 46,XY children reared as males, replacement doses of glucocorticoid (<a class="drug drug_general" data-topicid="8535" href="/d/drug information/8535.html" rel="external">hydrocortisone</a>) and mineralocorticoid (<a class="drug drug_general" data-topicid="8455" href="/d/drug information/8455.html" rel="external">fludrocortisone</a> acetate) are often sufficient to attenuate adrenal-derived androgen production enough to normalize growth and to prevent bone age advancement. Suppression of ACTH and DHEA is generally not necessary to maintain active androgens in the prepubertal range.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In children reared as females, somewhat higher doses may be needed to prevent excess production of androgens derived from adrenal precursors, particularly during adolescence.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>At the time of expected puberty, puberty is induced with low-dose androgens or estrogens. In undervirilized 46,XY males, <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> therapy may be used during childhood to augment penile size prior to initiation of puberty. (See  <a class="medical medical_review" href="/d/html/5814.html" rel="external">"Approach to the patient with delayed puberty", section on 'Therapy'</a>.)</p><p></p><p class="headingAnchor" id="H93046139"><span class="h1">11-BETA-HYDROXYLASE DEFICIENCY</span><span class="headingEndMark"> — </span>Deficiency of CYP11B1 (P450 11B1 or 11-beta-hydroxylase) (11OHD), affects 1 in 100,000 live births and accounts for up to 5 percent of adrenal steroidogenic defects [<a href="#rid78">78</a>]. In Jews of Moroccan ancestry, 11OHD prevalence is as high as 1 in 5000 due to the R448H founder mutation [<a href="#rid79">79,80</a>]. The phenotype of 11OHD is a mix of androgen excess (as in 21-hydroxylase deficiency [21OHD]) with mineralocorticoid excess as in combined 17-hydroxylase/17,20-lyase deficiency (17OHD), for the reasons described below.</p><p class="headingAnchor" id="H93046173"><span class="h2">Pathophysiology</span><span class="headingEndMark"> — </span>Deficiency of 11-beta-hydroxylase activity in the zona fasciculata blocks the conversions of 11-deoxycorticosterone (DOC) and 11-deoxycortisol to corticosterone and cortisol, respectively. The resulting increase in corticotropin (ACTH) secretion causes the accumulation of 11-deoxysteroid precursors and adrenocortical hyperplasia. Since CYP17A1 activities are intact and also stimulated by high ACTH concentrations, some of the upstream steroids are metabolized to adrenal-derived androgens.</p><p class="headingAnchor" id="H93046179"><span class="h2">Clinical presentation</span><span class="headingEndMark"> — </span>The clinical manifestations of the disorder result from high adrenal production of the mineralocorticoid DOC and androgen precursors, which are metabolized to active androgens in the adrenal and/or peripheral organs  (<a class="graphic graphic_figure graphicRef64361" href="/d/graphic/64361.html" rel="external">figure 6</a> and <a class="graphic graphic_table graphicRef104126" href="/d/graphic/104126.html" rel="external">table 1</a>). Consequently, the two characteristic clinical features are hypertension with hypokalemia, as found in any other form of mineralocorticoid excess, and androgen excess. Since 11-deoxycortisol has little biological activity and cannot substitute for cortisol as a glucocorticoid, however, these patients are paradoxically vulnerable to adrenal crises, although they are relatively protected by mineralocorticoid (DOC) excess.</p><p class="headingAnchor" id="H3574909305"><span class="h3">Clinical findings</span><span class="headingEndMark"> — </span>Classically, female newborns are identified with atypical genitalia, including clitoral enlargement and labioscrotal fusion as in 21OHD (see  <a class="medical medical_review" href="/d/html/5803.html" rel="external">"Evaluation of the infant with atypical genital appearance (difference of sex development)"</a>). Boys may have increased penile size, but unless born into a kindred known to carry 11OHD, they are often not diagnosed at birth or by newborn screening of 17-hydroxyprogesterone (17OHP), which is not as high in this disorder as it is in 21OHD. (See  <a class="medical medical_review" href="/d/html/145.html" rel="external">"Clinical manifestations and diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children"</a>.)</p><p>In children who are not diagnosed at birth, 11OHD presents as premature adrenarche, with body odor and axillary and pubic hair development. Somatic growth and bone age generally advance faster than in idiopathic premature adrenarche, suggesting the diagnosis of 11OHD.</p><p>Untreated children progress into isosexual or contrasexual precocious pseudopuberty. In one series of 25 patients with 11OHD, approximately half had relatively severe genital atypia or signs of hyperandrogenism [<a href="#rid81">81</a>]. The remainder presented in childhood with sexual precocity, early puberty in boys and acne in men, and hirsutism and menstrual irregularities in adolescent girls and young women.</p><p>Hypertension occurs in approximately two-thirds of patients, often early in life [<a href="#rid78">78,82</a>]. Although it is ascribed to DOC excess, the correlations between blood pressure and serum DOC concentrations [<a href="#rid81">81,83</a>] or severity of the deficiency based on genotype [<a href="#rid84">84</a>] are poor. A few patients with 11OHD have salt-wasting or hypotensive crises [<a href="#rid81">81,85-87</a>], but the reasons for this phenotypic heterogeneity are not known. As with 17OHD, hypertension is often accompanied by hypokalemia with suppression of plasma renin activity and aldosterone due to volume expansion. (See  <a class="medical medical_review" href="/d/html/140.html" rel="external">"Pathophysiology and clinical features of primary aldosteronism"</a>.)</p><p>The hypertension and hypokalemia distinguish 11OHD from 21OHD and HSD3B2 deficiency, and the androgen excess distinguishes 11OHD from 17OHD. As in 21OHD, untreated males may experience hyperplasia of adrenal rest tissue, which often presents as retroperitoneal or testicular masses that regress with treatment [<a href="#rid88">88,89</a>].</p><p>As with 21OHD, a milder or nonclassic form featuring androgen excess without hypertension has been described [<a href="#rid78">78,90-93</a>] (see <a class="local">'Clinical and biochemical features'</a> above). Nonclassic 11OHD should be considered in children with androgen excess and in hirsute or oligomenorrheic adolescent and adult women when symptoms began in childhood and 21OHD has been excluded. In nonclassic 11OHD, 17OHP is elevated but not as high as in 21OHD. Consequently, the evaluation of hirsute women should begin with 17OHP and only consider cosyntropin-stimulated 11-deoxycortisol to diagnose nonclassic 11OHD in selected cases. (See  <a class="medical medical_review" href="/d/html/145.html" rel="external">"Clinical manifestations and diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children"</a>.)</p><p class="headingAnchor" id="H93046419"><span class="h3">Biochemical findings</span><span class="headingEndMark"> — </span>Patients with classic CYP11B1 deficiency have a characteristic set of hormonal findings, often with hypokalemia:</p><p class="bulletIndent1"><span class="glyph">●</span>High serum concentrations of 11-deoxycortisol, DOC, androstenedione, and <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a>, with low cortisol and corticosterone  (<a class="graphic graphic_figure graphicRef64361" href="/d/graphic/64361.html" rel="external">figure 6</a> and <a class="graphic graphic_table graphicRef104126" href="/d/graphic/104126.html" rel="external">table 1</a>). Unlike in 21OHD, 11-oxygenated androgens are not produced, because of the 11-hydroxylase deficiency [<a href="#rid94">94</a>]. (See  <a class="medical medical_review" href="/d/html/145.html" rel="external">"Clinical manifestations and diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased urinary excretion of 11-deoxysteroid metabolites, most prominently tetrahydro metabolites of 11-deoxycortisol and DOC, which are normally present in trace quantities [<a href="#rid95">95</a>]. Urinary excretion of 17-ketosteroids and of all 19-carbon steroids, which reflects integrated androgen synthesis, is also increased.</p><p></p><p class="headingAnchor" id="H93046445"><span class="h2">Diagnosis and differential diagnosis</span><span class="headingEndMark"> — </span>In affected neonates, the diagnosis is most efficiently established by high basal and cosyntropin-stimulated serum 11-deoxycortisol concentrations with low cortisol or by increased urinary excretion of tetrahydro-11-deoxycortisol with low cortisol metabolites  (<a class="graphic graphic_figure graphicRef64361" href="/d/graphic/64361.html" rel="external">figure 6</a>) [<a href="#rid78">78,96,97</a>]. To diagnose mild or nonclassic 11OHD in adolescents and young adults, basal serum 11-deoxycortisol values may be normal, and cosyntropin stimulation testing is often required to establish the diagnosis [<a href="#rid98">98,99</a>], using the criteria of normal or near-normal cortisol plus 11-deoxycortisol &gt;1800 ng/dL (&gt;52 nmol/L). All diagnoses are preferably confirmed with genetic testing.</p><p>Because 17OHP also accumulates above the 11-beta-hydroxylase block, 17OHP is often moderately elevated in 11OHD. Consequently, the differential diagnosis for a young girl with mild virilization, androgen excess, and moderate 17OHP elevations includes nonclassic forms of 21OHD, 11OHD, and 3HSD3B2 deficiency. These diagnoses can only be distinguished by measurement of additional steroids including 11-deoxycortisol, DOC, and 17-hydroxypregnenolone, to pinpoint the enzymatic defect  (<a class="graphic graphic_figure graphicRef64361" href="/d/graphic/64361.html" rel="external">figure 6</a>).</p><p>The frequency of nonclassic disease is the highest for 21OHD; it is far less common for 11OHD and extremely rare for HSD3B2 deficiency [<a href="#rid100">100</a>]. Heterozygous carriers of 11OHD have no detectable biochemical abnormalities [<a href="#rid101">101</a>]. (See  <a class="medical medical_review" href="/d/html/147.html" rel="external">"Diagnosis and treatment of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency"</a>.)</p><p class="headingAnchor" id="H93048580"><span class="h2">Genetics</span><span class="headingEndMark"> — </span>The autosomal recessive disorder 11OHD is caused by mutations of the <em>CYP11B1</em> gene, located on chromosome 8q21-q22. Most mutations completely abolish the activity of the enzyme and include missense mutations that reduce enzyme activity [<a href="#rid80">80,102-104</a>], frameshifts [<a href="#rid105">105</a>], and nonsense mutations [<a href="#rid106">106,107</a>] that prevent synthesis of the enzyme. The founder mutation R448H is by far the most common and explains the high prevalence of 11OHD in Jews of Moroccan origin [<a href="#rid80">80</a>]. In two patients, the disorder occurred as a result of unequal recombination between the <em>CYP11B1</em> and <em>CYP11B2</em> genes [<a href="#rid108">108,109</a>], which is reminiscent of the genetic event leading to glucocorticoid-remediable aldosteronism (GRA). (See  <a class="medical medical_review" href="/d/html/122.html" rel="external">"Familial hyperaldosteronism", section on 'Familial hyperaldosteronism type I (FH type I) or glucocorticoid-remediable aldosteronism (GRA)'</a>.)</p><p class="headingAnchor" id="H93046689"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>The goals of therapy in <strong>children</strong> with 11OHD are to reduce mineralocorticoid and adrenal androgen precursor synthesis sufficiently to ameliorate the hypertension, hypokalemia, and androgen excess. (See  <a class="medical medical_review" href="/d/html/5800.html" rel="external">"Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Children are generally treated with glucocorticoids only, typically <a class="drug drug_general" data-topicid="8535" href="/d/drug information/8535.html" rel="external">hydrocortisone</a> (10 to 25 mg/m<sup>2</sup>), which is preferred over <a class="drug drug_general" data-topicid="9808" href="/d/drug information/9808.html" rel="external">prednisolone</a> (approximately 0.1 mg/kg) or <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> (up to 0.01 mg/kg), to lower ACTH secretion. Despite the proclivity for hypertension in 11OHD, hypotensive adrenal crises due to glucocorticoid deficiency can occur during significant illness.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8455" href="/d/drug information/8455.html" rel="external">Fludrocortisone</a> acetate is not necessary, and <a class="drug drug_general" data-topicid="9943" href="/d/drug information/9943.html" rel="external">spironolactone</a> is sometimes added to antagonize both androgens and mineralocorticoids, allowing reduced glucocorticoid dosing, particularly in adults. Given the phenotypic variability in this disease, treatment must be tailored to minimize the dose of glucocorticoid so as to prevent iatrogenic Cushing syndrome. (See  <a class="medical medical_review" href="/d/html/143.html" rel="external">"Epidemiology and clinical manifestations of Cushing syndrome"</a>.)</p><p></p><p>The response to therapy should be monitored both biochemically and clinically:</p><p class="bulletIndent1"><span class="glyph">●</span>Blood pressure should be normal, normokalemia should be restored, and 11-deoxycortisol concentrations should decrease although not necessarily to normal.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum androstenedione and <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> concentrations should be brought to age- and sex-specific normal range. In postpubertal boys and men, a serum androstenedione concentration higher than testosterone indicates that the androgens are adrenal derived and that disease control is poor.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A measurable plasma renin activity indicates suppression of mineralocorticoid synthesis, which can take months after starting therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinical monitoring includes assessment of virilization, growth velocity, and skeletal maturation (bone age) with attention to glucocorticoid-related side effects such as bruising, weight gain, and glucose intolerance. (See  <a class="medical medical_review" href="/d/html/5800.html" rel="external">"Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children", section on 'Monitoring and dose adjustment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In adolescent girls, facial hair growth and acne should be examined. Vaginal inadequacy in affected females may require reconstruction with one or more surgeries and vaginal dilation. (See  <a class="medical medical_review" href="/d/html/5800.html" rel="external">"Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children"</a>.)</p><p></p><p>In <strong>adult women</strong> with 11OHD, growth and bone age advancement are no longer concerns, but androgen excess and hypertension remain indications for treatment.</p><p><a class="drug drug_general" data-topicid="9943" href="/d/drug information/9943.html" rel="external">Spironolactone</a>, 25 to 200 mg/day, treats both the mineralocorticoid-mediated hypertension with hypokalemia and the androgen excess by blocking both the mineralocorticoid and androgen receptors. The main drawbacks of spironolactone are vaginal bleeding or spotting between menses and contraindication during pregnancy. The use of spironolactone to treat hyperandrogenism in premenopausal women is reviewed separately. (See  <a class="medical medical_review" href="/d/html/7444.html" rel="external">"Management of hirsutism in premenopausal women", section on 'Antiandrogens'</a>.)</p><p>There has been one successful pregnancy reported in a woman with 11OHD. A 26 year old who had been treated with <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> and <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> conceived when <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> citrate was added to induce ovulation [<a href="#rid110">110</a>]. Pregnancy in 11OHD is not as well studied as in 21OHD, but in both disorders, a goal of treatment for women attempting pregnancy is to suppress adrenal-derived progesterone production in the follicular phase.</p><p>In <strong>adult males</strong>, at a minimum, replacement doses of <a class="drug drug_general" data-topicid="8535" href="/d/drug information/8535.html" rel="external">hydrocortisone</a> should be administered to avoid the development of adrenal rest tumors.</p><p><a class="drug drug_general" data-topicid="9943" href="/d/drug information/9943.html" rel="external">Spironolactone</a> can cause gynecomastia and sexual dysfunction in males, whereas <a class="drug drug_general" data-topicid="8789" href="/d/drug information/8789.html" rel="external">eplerenone</a> and the potassium-sparing diuretics <a class="drug drug_general" data-topicid="10016" href="/d/drug information/10016.html" rel="external">triamterene</a> and <a class="drug drug_general" data-topicid="8550" href="/d/drug information/8550.html" rel="external">amiloride</a> are alternatives. As with other forms of mineralocorticoid excess, the hypertension may persist even after adequate treatment. (See  <a class="medical medical_review" href="/d/html/141.html" rel="external">"Treatment of primary aldosteronism", section on 'Medical therapy'</a>.)</p><p>Prenatal diagnosis of 11OHD may be established by measuring tetrahydro-11-deoxycortisol in amniotic fluid [<a href="#rid111">111</a>] or by sequencing the <em>CYP11B1</em> gene amplified from DNA in chorionic villus biopsy samples [<a href="#rid112">112</a>]. As in 21OHD, prenatal <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> reduces genital virilization in affected girls, but experience is much more limited than in 21OHD. In one report, a woman with two affected daughters was treated with dexamethasone (20 mcg/kg daily in three divided doses) from the fifth week of pregnancy to term and delivered a female infant with normal external genitalia [<a href="#rid112">112</a>]. (See  <a class="medical medical_review" href="/d/html/136.html" rel="external">"Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in adults", section on 'Pregnancy'</a>.)</p><p class="headingAnchor" id="H1699852"><span class="h1">P450 OXIDOREDUCTASE DEFICIENCY (APPARENT COMBINED CYP17A1 AND CYP21A2 DEFICIENCY)</span><span class="headingEndMark"> — </span>The clinical entity of apparent combined partial CYP17A1 and CYP21A2 deficiencies was first described in 1985 [<a href="#rid113">113</a>], while its genetic cause, cytochrome P450 oxidoreductase (<em>POR</em>) mutations, was not identified until 2004 [<a href="#rid24">24,26</a>]. The POR enzyme serves as an electron donor flavoprotein to cytochrome P450 (CYP) enzymes in the endoplasmic reticulum (microsomal or type II), which include steroidogenic enzymes (CYP17A1, CYP21A2, and CYP19A1 [aromatase]) and xenobiotic-metabolizing hepatic P450 enzymes. The biochemical presentation of POR deficiency (ORD) is characterized by apparent combined partial CYP17A1 and CYP21A2 deficiencies [<a href="#rid113">113</a>], with a large increase in pregnenolone and progesterone metabolites readily detectable by gas chromatography-mass spectrometry (GC-MS) analysis of a urine sample  (<a class="graphic graphic_figure graphicRef53155" href="/d/graphic/53155.html" rel="external">figure 3</a>) [<a href="#rid26">26,114</a>].</p><p>Approximately 100 cases of ORD have been reported [<a href="#rid24">24-26,115-119</a>]; a significant number of reported patients had been previously misdiagnosed with CYP17A1, CYP19A1, and CYP21A2 deficiency, respectively [<a href="#rid24">24,25,120</a>]. Considering the number of patients reported in recent years, it appears likely that ORD might be the second most common cause of congenital adrenal hyperplasia (CAH) in some populations, such as Korea and Japan.</p><p class="headingAnchor" id="H112544786"><span class="h2">Clinical features</span><span class="headingEndMark"> — </span>ORD has two characteristic clinical features. First, affected neonates may present with severe undervirilization in boys and virilization in girls. In addition, patients may present with a complex, predominantly craniofacial pattern, resembling that previously described by Antley and Bixler [<a href="#rid121">121</a>] and therefore termed Antley-Bixler syndrome (ABS).</p><p>ORD is not associated with mineralocorticoid deficiency, and in some patients, preferential inhibition of 17-hydroxylase over 21-hydroxylase by specific <em>POR</em> mutants may even result in mineralocorticoid accumulation [<a href="#rid122">122</a>]. Mineralocorticoid-related hypertension is not a feature of ORD, although two young adults with ORD and coincident arterial hypertension have been described [<a href="#rid24">24</a>].</p><p>In stark contrast to 21-hydroxylase deficiency (21OHD) due to <em>CYP21A2</em> mutations, sex steroids in patients with ORD are low normal or decreased as a consequence of concomitant CYP17A1 dysfunction. The clinical presentation of ORD, however, comprises the entire spectrum of differences of sex development (DSD). This spectrum includes undervirilization of genetically male individuals (46,XY DSD), varying from borderline micropenis to severe perineoscrotal hypospadias, and virilization of genetically female individuals (46,XX DSD), varying from mild clitoral hypertrophy to Prader IV to V virilization  (<a class="graphic graphic_figure graphicRef52525" href="/d/graphic/52525.html" rel="external">figure 5</a>).</p><p>The paradox of maternal virilization during pregnancy and severe neonatal virilization of affected girls with ORD despite postnatal androgen deficiency has been explained by increased flux of precursor steroids through an alternative pathway to dihydrotestosterone during fetal life, which declines shortly after birth [<a href="#rid26">26</a>]. In addition, some <em>POR</em> mutants may also affect aromatase activity [<a href="#rid123">123</a>], in particular R457H, the most frequently found mutation in the Japanese population, which is invariably associated with 46,XX DSD in homozygous neonates [<a href="#rid116">116,124</a>].</p><p>Pubertal development in ORD is not well studied but appears to be dominated by the consequences of sex steroid deficiency [<a href="#rid116">116</a>]. Cystic ovaries and also larger ovarian cysts at risk of rupture are a common finding during early adolescence, as a consequence of gonadotropin upregulation due to sex steroid deficiency (similar to findings in 17OHD and 21OHD).</p><p>Malformations reported in patients affected by ORD constitute one type of ABS [<a href="#rid121">121</a>]; the other type lacks disordered steroidogenesis. Skeletal malformations include craniofacial malformations such as midface hypoplasia with low-set ears and pear-shaped nose. Craniosynostosis in variable severity may require ventriculoperitoneal shunting. Frequently observed features include arachnodactyly, clinodactyly, and radiohumeral synostosis. In severely affected children, bowed femora with neonatal fractures and choanal atresia may be observed. The mechanism of ABS malformations probably derives from concomitant loss of lanosterol demethylase (CYP51A1) activity, an enzyme required for de novo cholesterol biosynthesis, which also uses POR as a co-factor. Retinoic acid toxicity due to impaired activity of the CYP26 family enzymes, which also use POR and degrade retinoic acid, might also contribute. The loss of cholesterol synthesis during embryogenesis impairs signaling molecules important for body patterning and development [<a href="#rid116">116,117,125-129</a>]. POR also serves as co-factor for enzymes involved in hepatic drug and xenobiotic metabolism, namely CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Disease-causing mutations in POR thus variably alter drug metabolism [<a href="#rid130">130-135</a>].</p><p class="headingAnchor" id="H112544780"><span class="h2">Diagnosis and differential diagnosis</span><span class="headingEndMark"> — </span>Comprehensive urine GC-MS analysis is the gold standard for the diagnosis of ORD, and it identifies the accumulation of pregnenolone and progesterone metabolites, increased 17-hydroxyprogesterone (17OHP) metabolites and decreased androgen metabolites  (<a class="graphic graphic_figure graphicRef53155" href="/d/graphic/53155.html" rel="external">figure 3</a>) [<a href="#rid114">114</a>]. Increased pregnenolone and progesterone metabolite excretion may occur in some heterozygous parents.</p><p>Characteristically, mothers carrying a child affected by ORD have low serum estriol, which might be found in the prenatal triple marker test; subsequent analysis of maternal urine reveals a characteristic steroid precursor pattern facilitating prenatal diagnosis [<a href="#rid114">114,136</a>]. Maternal virilization, associated with a high excretion of specific androgen metabolites and manifesting around mid-gestation, is frequently but not invariably observed during these pregnancies [<a href="#rid26">26,114,137</a>].</p><p>Individual plasma steroid measurements are less informative than urinary steroid metabolite analysis; in particular, hallmark steroids of 17OHD and 21OHD may be present in variable combinations, which may result in misdiagnosis of affected patients [<a href="#rid120">120</a>]. As a result of 21-hydroxylase inhibition, serum 17OHP may be elevated but to a lesser degree than in 21OHD. Consequently, only some of the patients are picked up at neonatal CAH screening [<a href="#rid116">116,124</a>]. Serum progesterone is consistently high and 19-carbon steroids consistently low, but these data by themselves are not diagnostic.</p><p>ABS may also occur in individuals with fibroblast growth factor receptor 2 (<em>FGFR2</em>) mutations [<a href="#rid138">138-140</a>]. However, the <em>FGFR2</em> gene in patients with ORD is normal [<a href="#rid24">24,26,125</a>], and patients with proven <em>FGFR2</em> mutations do not present with disordered steroidogenesis or disordered sex development [<a href="#rid139">139</a>]. Genetic analysis of a cohort of patients with ABS phenotype revealed clear segregation of <em>FGFR2</em> and POR mutations [<a href="#rid117">117</a>]. Thus, it is important to recognize that ABS only serves as a descriptive term for a distinct pattern of bone malformations but is <strong>not</strong> an alternative term for ORD. ABS may occur in individuals with <em>POR</em> mutations, in individuals with <em>FGFR2</em> mutations, and in individuals with other or hitherto unknown mutations.</p><p class="headingAnchor" id="H1699866"><span class="h2">POR mutations</span><span class="headingEndMark"> — </span>ORD is an autosomal recessive disorder. Most patients are compound heterozygous, and two completely inactive or deleted alleles have not been reported. A287P is the most frequently reported mutation in White individuals [<a href="#rid117">117</a>]. R457H is predominantly found in Japanese populations [<a href="#rid115">115,116,124</a>] and represents a global founder mutation [<a href="#rid141">141</a>].</p><p>Genotype-phenotype correlations are not fully established, yet certain patterns are emerging between specific mutations and phenotypic expression of ABS [<a href="#rid116">116</a>].</p><p class="headingAnchor" id="H1699873"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>The goals of treatment in ORD are to replace glucocorticoid deficiency when present and to restore desired secondary sexual characteristics at time of puberty. (See  <a class="medical medical_review" href="/d/html/155.html" rel="external">"Treatment of adrenal insufficiency in adults"</a> and  <a class="medical medical_review" href="/d/html/5814.html" rel="external">"Approach to the patient with delayed puberty", section on 'Therapy'</a>.)</p><p>A cosyntropin stimulation test should be performed to establish the degree of glucocorticoid deficiency as affected patients may be at risk of a life-threatening adrenal crisis if not adequately replaced [<a href="#rid124">124,139</a>]. (See  <a class="medical medical_review" href="/d/html/157.html" rel="external">"Diagnosis of adrenal insufficiency in adults", section on 'ACTH stimulation tests'</a>.)</p><p>Some patients may have a normal cortisol response to corticotropin (ACTH) and do not require glucocorticoid replacement [<a href="#rid26">26</a>]. Most ORD patients have normal baseline secretion but fail to achieve a completely normal cortisol response [<a href="#rid114">114,116,142</a>]. If the response is a borderline fail, stress dose cover for intercurrent illness and surgery might be advised. However, if the test is clearly failed, permanent <a class="drug drug_general" data-topicid="8535" href="/d/drug information/8535.html" rel="external">hydrocortisone</a> replacement is recommended. As there is no accumulation of androgens, ACTH suppression is unnecessary, and hydrocortisone replacement should be administered in the lowest dose possible. (See  <a class="medical medical_review" href="/d/html/155.html" rel="external">"Treatment of adrenal insufficiency in adults", section on 'Glucocorticoid replacement for all patients'</a> and  <a class="medical medical_review" href="/d/html/5825.html" rel="external">"Treatment of adrenal insufficiency in children", section on 'Glucocorticoids'</a>.)</p><p>Mineralocorticoid replacement is not required, and blood pressure requires careful monitoring. If mineralocorticoid precursor accumulation causes hypertension as in 17OHD, <a class="drug drug_general" data-topicid="9943" href="/d/drug information/9943.html" rel="external">spironolactone</a> can be used to control mineralocorticoid-mediated hypertension [<a href="#rid24">24</a>].</p><p>There is insufficient information on pubertal development in ORD, but it appears that puberty needs to be induced with sex steroid therapy in most individuals. (See  <a class="medical medical_review" href="/d/html/5814.html" rel="external">"Approach to the patient with delayed puberty", section on 'Therapy'</a>.)</p><p>ABS malformations require supportive treatment, including orthopedic and surgical management, which may include ventriculoperitoneal shunts and tracheostomy. The most severely affected patients may have decreased survival due to malformation-related complications [<a href="#rid136">136</a>]. However, mildly affected children are likely to achieve normal life expectancy.</p><p class="headingAnchor" id="H1699880"><span class="h1">HEXOSE-6-PHOSPHATE-DEHYDROGENASE DEFICIENCY (APPARENT CORTISONE REDUCTASE DEFICIENCY)</span><span class="headingEndMark"> — </span>Apparent cortisone reductase deficiency (ACRD) is a rare, autosomal recessive disorder that is characterized by apparently reduced activity of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (HSD11B1), resulting in reduced regeneration of cortisol from cortisone  (<a class="graphic graphic_figure graphicRef62897" href="/d/graphic/62897.html" rel="external">figure 7</a>). HSD11B1 does not function as a dehydrogenase in vivo, most likely because it colocalizes with hexose-6-phosphate-dehydrogenase (H6PDH) to face the lumen of the endoplasmic reticulum [<a href="#rid143">143</a>]. H6PDH generates the NADPH co-factor required for HSD11B1 to perform the reaction in the cortisone reductase direction preferentially, and this activity is disrupted in ACRD.</p><p>ACRD is characterized by an increase in urinary cortisone metabolites, while concurrently cortisol metabolites are decreased  (<a class="graphic graphic_figure graphicRef62897" href="/d/graphic/62897.html" rel="external">figure 7</a>). The compensatory increase in corticotropin (ACTH) production stimulates increases in adrenal androgen precursors [<a href="#rid143">143</a>].</p><p class="headingAnchor" id="H159860099"><span class="h2">Clinical presentation</span><span class="headingEndMark"> — </span>ACRD clinically presents with hyperandrogenism, manifesting as premature pubarche or with oligomenorrhea, acne, and hirsutism (similar to 21OHD). Genetically confirmed ACRD has been described in approximately 10 patients [<a href="#rid144">144-150</a>]. Given the lack of clinical signs and symptoms that would distinguish ACRD from other causes of androgen excess and the added difficulty that urinary steroid profiling with GC-MS is needed to establish the diagnosis, the true incidence of the disorder might be underestimated.</p><p class="headingAnchor" id="H4222216069"><span class="h2">Hormonal criteria for diagnosis</span><span class="headingEndMark"> — </span>GC-MS analysis of urine has a very high sensitivity and characteristically shows an increase in the cortisone metabolite tetrahydrocortisone (THE) while the cortisol metabolites tetrahydrocortisol (THF) and 5-alpha-tetrahydrocortisol (5a-THF) are decreased. As a consequence, the ratio of (5a-THF + THF)/THE is reduced, which serves as diagnostic criterion for ACRD  (<a class="graphic graphic_figure graphicRef62897" href="/d/graphic/62897.html" rel="external">figure 7</a>).</p><p class="headingAnchor" id="H1699894"><span class="h2">H6PD mutations</span><span class="headingEndMark"> — </span>ACRD is an autosomal recessive disorder caused by homozygous and compound heterozygous hexose-6-phosphate-dehydrogenase (<em>H6PD</em>) mutations [<a href="#rid147">147,151</a>]. Some patients with ACRD also have polymorphic <em>HSD11B1</em> sequence variants that are not disease-causing mutations [<a href="#rid145">145,152,153</a>].</p><p class="headingAnchor" id="H1699901"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>The main goal of treatment in ACRD is control of androgen excess and related signs and symptoms. This can be achieved by modest doses of glucocorticoids (<a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> &lt;0.25 mg/day, <a class="drug drug_general" data-topicid="9808" href="/d/drug information/9808.html" rel="external">prednisolone</a> &lt;5 mg/day, <a class="drug drug_general" data-topicid="8535" href="/d/drug information/8535.html" rel="external">hydrocortisone</a> &lt;20 mg/day) to normalize ACTH and thus adrenal androgen production. Clinical and laboratory assessments are used to titrate therapy, similar to 21OHD. (See  <a class="medical medical_review" href="/d/html/136.html" rel="external">"Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in adults"</a>.)</p><p class="headingAnchor" id="H1699908"><span class="h1">PAPSS2 DEFICIENCY (APPARENT DHEA SULFOTRANSFERASE DEFICIENCY)</span><span class="headingEndMark"> — </span>3'-phosphoadenosine-5'-phosphosulfate (PAPS) synthase type 2 (PAPSS2) deficiency is a rare disorder originally described in its severe form as spondyloepimetaphyseal dysplasia or autosomal recessive brachyolmia in a Pakistani kindred [<a href="#rid154">154</a>]. Subsequently, a patient of Turkish origin [<a href="#rid155">155</a>] was described with androgen excess and only subtle bone dysplasia. An additional 20 to 30 cases have been identified with variable skeletal features; when performed, careful endocrine evaluations reveal disordered adrenal steroidogenesis [<a href="#rid156">156</a>].</p><p class="headingAnchor" id="H3267481659"><span class="h2">Pathophysiology</span><span class="headingEndMark"> — </span>PAPSS2 deficiency is characterized by apparent inability of the adrenal androgen precursor dehydroepiandrosterone (DHEA) to be conjugated via the sulfate donor PAPS to its sulfate ester DHEAS  (<a class="graphic graphic_figure graphicRef74694" href="/d/graphic/74694.html" rel="external">figure 8</a>). Clinically, PAPSS2 deficiency presents in childhood with androgen excess resulting in premature pubarche that progresses to oligomenorrhea, secondary amenorrhea, hirsutism, and acne. The sulfonation defect exists in chondrocytes and also affects bone development, so that patients may present with bone dysplasia and associated malformation phenotype.</p><p>Adrenal DHEA is a major androgen precursor in women. Unconjugated DHEA can be metabolized to active androgens, whereas the conversion of DHEAS to androgens requires initial cleavage of the sulfate group. Most adrenal DHEA is sulfonated to DHEAS before entering the circulation, and interconversion between DHEA and DHEAS in the body favors DHEAS, due to high hepatic sulfonation activity. Thus, impaired DHEA sulfonation increases the amount of DHEA available for conversion to active androgens.</p><p>DHEA sulfotransferase (SULT2A1) is the major enzyme responsible for DHEA sulfonation, converting DHEA to DHEAS mainly in the adrenal glands and the liver  (<a class="graphic graphic_figure graphicRef74694" href="/d/graphic/74694.html" rel="external">figure 8</a>) [<a href="#rid157">157</a>]. The sulfate donor PAPS is required by all sulfotransferases, including SULT2A1. In humans, PAPS is synthesized by the two isoforms of PAPS synthase, PAPSS1 and PAPSS2. PAPSS2 is predominantly expressed in the major sites of DHEA sulfation, adrenal and liver (as well as chondrocytes), while PAPSS1 is ubiquitously expressed [<a href="#rid155">155</a>]. Both PAPS proteins have two domains associated with distinct enzymatic activities: the ATP sulfurylase domain converting ATP and sulfate to adenosine-5'-phosphosulfate (APS), and the APS kinase domain that generates PAPS from APS and ATP [<a href="#rid157">157</a>].</p><p class="headingAnchor" id="H3336789148"><span class="h2">Clinical presentation and genetics</span><span class="headingEndMark"> — </span>The first patient with PAPSS2 deficiency identified due to androgen excess was a girl presenting with premature pubarche and advanced bone age at age six years, followed by progression to the phenotype observed in nonclassic 21OHD, including oligomenorrhea, acne, hirsutism, and eventually secondary amenorrhea at the age of 13 years [<a href="#rid155">155</a>]. Her circulating androgens, including androstenedione, <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a>, dihydrotestosterone, and DHEA were high, but DHEAS was below the detection limit of the assay, suggesting that impaired DHEA sulfonation was the cause of androgen excess. Detailed radiograph analysis of this girl showed mild bone dysplasia in the lumbar and thoracic spine but no involvement of the long bones; however, she had no clinical symptoms of bone dysplasia. Genetic analysis showed compound heterozygous mutations in the <em>PAPSS2</em> gene, which is located on chromosome 10 (10q22-q24): one missense mutation affecting the APS kinase domain and a nonsense mutation resulting in early truncation of the ATP sulfurylase domain [<a href="#rid155">155</a>].</p><p>A family with two postpubertal brothers who are compound heterozygotes for a null frame-shift allele and mutation G270D has also been described [<a href="#rid156">156,158</a>]. The mother, who is a carrier for the null allele, had chronic anovulation and enhanced conversion of DHEA to androgens. These findings suggest that heterozygous carriers might have clinical manifestations.</p><p class="headingAnchor" id="H2795246849"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>The goal of the treatment in PAPSS2 deficiency is the control of androgen excess and its clinical consequences. Glucocorticoid in moderate dose to lower adrenal androgens, as for apparent cortisone reductase deficiency (ACRD), is an option but risks overtreatment. Boys might not require treatment upon reaching adulthood, whereas women will likely require chronic therapy. Additional options for the treatment of hyperandrogenism in premenopausal women are reviewed separately. (See <a class="local">'P450 oxidoreductase deficiency (apparent combined CYP17A1 and CYP21A2 deficiency)'</a> above and  <a class="medical medical_review" href="/d/html/7444.html" rel="external">"Management of hirsutism in premenopausal women", section on 'Management'</a>.)</p><p class="headingAnchor" id="H2642991429"><span class="h1">LIPOID CONGENITAL ADRENAL HYPERPLASIA</span><span class="headingEndMark"> — </span>Lipoid congenital adrenal hyperplasia (LCAH) is among the rarest and when complete the most severe form of congenital adrenal steroidogenic defect  (<a class="graphic graphic_table graphicRef76865" href="/d/graphic/76865.html" rel="external">table 2</a> and <a class="graphic graphic_figure graphicRef56021" href="/d/graphic/56021.html" rel="external">figure 9</a>).</p><p class="headingAnchor" id="H409268001"><span class="h2">Pathophysiology and genetics</span><span class="headingEndMark"> — </span>LCAH is characterized by deficiency of all or nearly all adrenal and gonadal steroid hormones, increased corticotropin (ACTH) secretion, and marked adrenal hyperplasia with progressive accumulation of cholesterol esters.</p><p>The defect in the majority of patients with LCAH resides in a gene on chromosome 8 that codes for the steroidogenic acute regulatory protein (StAR) [<a href="#rid159">159,160</a>]. This mitochondrial phosphoprotein normally mediates the acute response to steroidogenic stimuli by increasing cholesterol transport from the outer to the inner mitochondrial membrane [<a href="#rid159">159,161-163</a>], resulting in increased conversion of cholesterol to pregnenolone, the first step in steroid biosynthesis  (<a class="graphic graphic_figure graphicRef56021" href="/d/graphic/56021.html" rel="external">figure 9</a>). Hence, mutations may decrease all pathways of steroidogenesis. <em>StAR</em> is expressed in the adrenal cortex and steroidogenic cells of the gonads but not in the placenta, and placental synthesis of progesterone, which requires CYP11A1, is unaffected in LCAH [<a href="#rid62">62</a>].</p><p>The role of StAR has been studied by sequencing the gene in patients with LCAH [<a href="#rid160">160,164-167</a>]. More than 100 patients and 40 different mutations have been described [<a href="#rid168">168</a>]; the mutated StAR proteins were inactive in functional assays. Steroidogenic cells that lack StAR are capable of low levels of steroidogenesis but progressively accumulate cholesterol esters. Experts have concluded that the LCAH phenotype is the result of two separate events:</p><p class="bulletIndent1"><span class="glyph">●</span>An initial defect in steroidogenesis due to the <em>StAR</em> mutation</p><p class="bulletIndent1"><span class="glyph">●</span>A subsequent further defect in steroidogenesis due to cellular damage from accumulated cholesterol esters</p><p></p><p>The "two hit" hypothesis is supported by clinical data from girls with LCAH, in whom the ovary makes negligible steroids during fetal life and childhood. At the time of expected puberty, girls with LCAH sometimes develop breasts and even menses [<a href="#rid169">169</a>], but estrogen production fails over months to years as cholesterol esters accumulate in the steroidogenic cells of the ovary.</p><p>In addition to classic LCAH, a nonclassic form has been described [<a href="#rid170">170</a>]. These patients typically present in childhood with isolated glucocorticoid deficiency because a much higher quantity of cortisol production is required to fulfill its biologic function than for other classes of steroids. Thus, these first patients were identified in kindreds with presumed familial glucocorticoid deficiency (FGD). Mutation R188C, which retains approximately 7 percent activity, is the most common allele, but others (eg, R192C, G221D, L260P, and F267) have been described [<a href="#rid171">171</a>]. Sex steroid deficiency might become manifest at the time of expected puberty, particularly in boys.</p><p class="headingAnchor" id="H3402240681"><span class="h2">Clinical presentation</span><span class="headingEndMark"> — </span>Patients with complete LCAH caused by <em>StAR</em> mutations typically have severe adrenal insufficiency very soon after birth, although they occasionally present later in infancy [<a href="#rid172">172</a>] with vomiting, diarrhea, volume depletion, hyponatremia, and hyperkalemia. Male infants usually have female external genitalia due to lack of testicular androgen production. In comparison, female infants are normally developed at birth, and occasional girls undergo spontaneous partial pubertal development [<a href="#rid173">173</a>].</p><p>The transient sparing of ovarian steroid synthesis has been attributed to the dormancy of ovarian steroidogenesis until puberty, thereby preventing the excess cholesterol accumulation and subsequent damage that the adrenal glands and testes suffer. The same explanation might account for the detectable, if very low, serum aldosterone concentrations driven by high plasma renin activity in these patients; the adrenocortical cells destined to become glomerulosa cells are minimally stimulated in utero [<a href="#rid169">169</a>].</p><p>Boys with nonclassic LCAH may present with adrenal insufficiency but have normal male external genitalia.</p><p class="headingAnchor" id="H1526678185"><span class="h3">Biochemical findings</span><span class="headingEndMark"> — </span>Patients with LCAH have very low serum cortisol and aldosterone concentrations and very high plasma ACTH concentrations and plasma renin activity [<a href="#rid174">174-176</a>]. Production of gonadal steroids is also impaired, and serum gonadotropin concentrations are high (for age) in newborns and in children as young as 4.5 years old [<a href="#rid176">176</a>].</p><p class="headingAnchor" id="H4216595219"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis should be considered in a neonate with any symptoms or signs of adrenal insufficiency and ambiguous or female genitalia. The diagnosis is confirmed by the absence of demonstrable steroid biosynthetic activity by the adrenals and, in boys, also the gonads.</p><p class="headingAnchor" id="H1041637917"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>Classic LCAH has been fatal during infancy in two-thirds of reported patients [<a href="#rid176">176</a>], but some patients survive [<a href="#rid169">169,177</a>]. Glucocorticoid and mineralocorticoid deficiency is managed by replacement therapy as in any form of adrenal insufficiency [<a href="#rid176">176</a>]. These replacement regimens are reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/5825.html" rel="external">"Treatment of adrenal insufficiency in children"</a> and  <a class="medical medical_review" href="/d/html/155.html" rel="external">"Treatment of adrenal insufficiency in adults"</a>.)</p><p>Replacement therapy alone is required, as the high ACTH will not cause excess of unwanted steroids [<a href="#rid176">176</a>]. At the time of puberty, low-dose estradiol therapy is provided to complete the development of secondary sexual characteristics, as all patients are phenotypically female. Those with 46,XX karyotype and intact uterus require periodic progesterone withdrawal bleeding as well. Surprisingly, one patient with classic LCAH homozygous for the L275P mutation has had two pregnancies and live births following <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> citrate ovulation induction with progesterone support during early pregnancy [<a href="#rid178">178</a>]. (See  <a class="medical medical_review" href="/d/html/5814.html" rel="external">"Approach to the patient with delayed puberty", section on 'Estradiol therapy'</a>.) </p><p>In nonclassic LCAH, glucocorticoid replacement therapy alone is required, at least during childhood. Pubertal development and fertility in these patients have not been studied adequately.</p><p class="headingAnchor" id="H2060973991"><span class="h1">CHOLESTEROL SIDE-CHAIN CLEAVAGE ENZYME (CYP11A1) DEFICIENCY</span><span class="headingEndMark"> — </span>Before the discovery of steroidogenic acute regulatory protein (StAR), it was assumed that the defect in lipoid congenital adrenal hyperplasia (LCAH) would reside in the <em>CYP11A1</em> gene encoding the cholesterol side-chain cleavage enzyme (cytochrome P450 11A1, CYP11A1). However, CYP11A1 is required for biosynthesis of progesterone, and placental progesterone synthesis from the syncytiotrophoblast, which is fetal tissue, is believed to be necessary for the maintenance of pregnancy. Therefore, complete CYP11A1 deficiency was thought to be lethal, and initial reports failed to find CYP11A1 mutations in patients with LCAH [<a href="#rid165">165,166</a>].</p><p>Subsequently, two patients with LCAH were shown to have heterozygous mutations of <em>CYP11A1</em> [<a href="#rid167">167,168</a>]. The important difference from the usual presentation of LCAH is that the adrenals are not lipid laden in P450 11A1 deficiency. In addition to adrenal insufficiency, 46,XY individuals may have phenotypically female external genitalia at birth [<a href="#rid174">174,179</a>].</p><p class="headingAnchor" id="H2816289005"><span class="h2">Pathophysiology and genetics</span><span class="headingEndMark"> — </span>CYP11A1, encoded by <em>CYP11A1,</em> catalyzes the conversion of cholesterol to pregnenolone in mitochondria in steroidogenic cells. Theoretically, complete deficiency of the enzyme should be lethal because of placental insufficiency, as described above. Among the approximately 30 patients with CYP11A1 deficiency, the R451W mutation from eastern Turkey is most common [<a href="#rid180">180</a>]. Some patients harbor two null alleles [<a href="#rid179">179</a>], which is difficult to reconcile with the presumed requirement of progesterone to maintain pregnancy [<a href="#rid168">168</a>]. Affected patients with apparent haploinsufficiency have been described [<a href="#rid174">174,181</a>]. A CYP11A1 variant E314K is now recognized as a common disease-causing allele in children with congenital cortisol deficiency [<a href="#rid182">182</a>].</p><p class="headingAnchor" id="H1812903188"><span class="h2">Clinical presentation and biochemical features</span><span class="headingEndMark"> — </span>The clinical presentation is similar to LCAH with more variable onset of adrenal insufficiency and a spectrum of external genitalia from complete female to normal male [<a href="#rid168">168</a>]. Serum cortisol is low with high plasma corticotropin (ACTH). Other adrenal and gonadal steroids and gonadotropins vary with the severity of the disease. The adrenal glands are not markedly enlarged unlike most, but not all, cases of LCAH due to <em>StAR</em> mutations.</p><p class="headingAnchor" id="H1479646313"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>Glucocorticoid and mineralocorticoid deficiency is treated by replacement therapy as described above for LCAH. Many, but not all, patients require sex steroid therapy at the time of expected puberty, depending on the severity of the defect. (See  <a class="medical medical_review" href="/d/html/155.html" rel="external">"Treatment of adrenal insufficiency in adults"</a> and  <a class="medical medical_review" href="/d/html/5814.html" rel="external">"Approach to the patient with delayed puberty", section on 'Therapy'</a>.)</p><p class="headingAnchor" id="H2260944454"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112671.html" rel="external">"Society guideline links: Classic and nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency"</a>.)</p><p class="headingAnchor" id="H159860236"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>21-hydroxylase deficiency (21OHD)</strong> – The most frequent cause of congenital adrenal hyperplasia (CAH) is 21-hydroxylase deficiency (21OHD). Several less common causes of CAH exist. (See  <a class="medical medical_review" href="/d/html/145.html" rel="external">"Clinical manifestations and diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children"</a> and  <a class="medical medical_review" href="/d/html/147.html" rel="external">"Diagnosis and treatment of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CYP17A1 deficiencies</strong> – The cytochrome P450 17A1 enzyme (CYP17A1) catalyzes both the 17-hydroxylase reaction, which forms 17-hydroxysteroids, and the 17,20-lyase reaction, which cleaves 21-carbon 17-hydroxysteroids to 19-carbon 17-keto androgen precursors [<a href="#rid2">2</a>]. Most defects in CYP17A1 impair both enzymatic activities and cause combined 17-hydroxylase/17,20-lyase deficiency (17OHD). These deficiencies impair both adrenal and gonadal function. The classic presentation of <strong>severe</strong> 17OHD includes hypertension, primary amenorrhea, absence of secondary sexual characteristics, and minimal body hair in phenotypic females, who can have 46,XX or 46,XY karyotype  (<a class="graphic graphic_table graphicRef104126" href="/d/graphic/104126.html" rel="external">table 1</a> and <a class="graphic graphic_figure graphicRef52616" href="/d/graphic/52616.html" rel="external">figure 2</a>). Approximately 100 different mutations in the <em>CYP17A1</em> gene, which is located on chromosome 10q24.3, have been identified. (See <a class="local">'CYP17A1 deficiencies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>3-beta-hydroxysteroid dehydrogenase type 2 deficiency</strong> <strong>(HSD3B2)</strong> – This is a rare form of CAH in which synthesis of all active steroid hormones is impaired. HSD3B2 catalyzes the reactions that establish the 3-keto-delta-4 A-ring structure found in the major endogenous progestogens, mineralocorticoids, glucocorticoids, and androgens, including the precursors of dihydrotestosterone and estrogens. This disorder impairs both adrenal and gonadal steroid production. Much like 21OHD, most patients present as neonates or in early infancy with clinical manifestations of both cortisol and aldosterone deficiency, with feeding difficulties, vomiting, volume depletion, hyponatremia, and hyperkalemia  (<a class="graphic graphic_figure graphicRef74160" href="/d/graphic/74160.html" rel="external">figure 4</a>). Girls have mild androgen excess, due to the conversion of delta-5 steroids to active androgens via the type 1 isoenzyme in peripheral tissues. (See <a class="local">'3-beta-hydroxysteroid dehydrogenase type 2 deficiency'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>11-beta-hydroxylase deficiency</strong> – Deficiency of CYP11B1, or 11-beta-hydroxylase deficiency (11OHD), features the androgen excess of 21OHD and mineralocorticoid excess of 17OHD. The clinical manifestations of the disorder result from high adrenal production of the mineralocorticoid 11-deoxycorticosterone (DOC) and the adrenal androgen precursors  (<a class="graphic graphic_figure graphicRef64361" href="/d/graphic/64361.html" rel="external">figure 6</a> and <a class="graphic graphic_table graphicRef104126" href="/d/graphic/104126.html" rel="external">table 1</a>). Consequently, the two characteristic clinical features are hypertension with hypokalemia, as with any other form of mineralocorticoid excess and androgen excess. The autosomal recessive disorder 11OHD is caused by mutations of the <em>CYP11B1</em> gene, located on chromosome 8q21-q22. (See <a class="local">'11-beta-hydroxylase deficiency'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>P450 oxidoreductase deficiency (apparent combined CYP17A1 and CYP21A2 deficiency)</strong> – P450 oxidoreductase deficiency (apparent combined CYP17A1 and CYP21A2 deficiency) is an autosomal recessive disorder caused by mutations in the flavoprotein co-factor of the enzymes CYP17A1, CYP21A2, and CYP19A1 (aromatase). The biochemical presentation of P450 oxidoreductase (POR) deficiency (ORD) combines apparent partial CYP17A1 and CYP21A2 deficiencies. This disorder has two characteristic clinical features. First, affected neonates may present with severe undervirilization in boys and severe virilization in girls. In addition, patients may present with a complex, predominantly craniofacial skeletal dysplasias, termed Antley-Bixler syndrome (ABS). The goals of treatment in ORD are to replace glucocorticoid deficiency when present and to restore desired secondary sexual characteristics at the time of normal puberty  (<a class="graphic graphic_figure graphicRef53155" href="/d/graphic/53155.html" rel="external">figure 3</a>). (See <a class="local">'P450 oxidoreductase deficiency (apparent combined CYP17A1 and CYP21A2 deficiency)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hexose-6-phosphate-dehydrogenase deficiency (apparent cortisone reductase deficiency [ACRD])</strong> – Hexose-6-phosphate-dehydrogenase deficiency (apparent cortisone reductase deficiency [ACRD]) is an autosomal recessive disorder caused by mutations within the <em>H6PD</em> gene, encoding hexose-6-phosphate dehydrogenase (H6PDH). ACRD clinically manifests with hyperandrogenism, manifesting as premature pubarche or with oligomenorrhea, acne, and hirsutism (similar to nonclassic 21OHD). (See <a class="local">'Hexose-6-phosphate-dehydrogenase deficiency (apparent cortisone reductase deficiency)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PAPSS2 deficiency (apparent DHEA sulfotransferase deficiency) </strong>–<strong> </strong>PAPSS2 deficiency (apparent DHEA sulfotransferase deficiency) is an extremely rare disorder characterized by apparent inability to convert the adrenal androgen precursor dehydroepiandrosterone (DHEA) to its sulfate ester DHEAS  (<a class="graphic graphic_figure graphicRef74694" href="/d/graphic/74694.html" rel="external">figure 8</a>). Clinically, 3'-phosphoadenosine-5'-phosphosulfate synthase type 2 (PAPSS2) deficiency manifests with androgen excess resulting in premature pubarche and later by oligomenorrhea, secondary amenorrhea, hirsutism, and acne. However, failure to sulfonate also affects bone development, and patients may present with bone dysplasia and associated malformation phenotype. This disorder is due to mutations in the <em>PAPSS2</em> gene, which is located on chromosome 10 (10q22-q24). (See <a class="local">'PAPSS2 deficiency (apparent DHEA sulfotransferase deficiency)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lipoid congenital adrenal hyperplasia (LCAH)</strong> – LCAH,<strong> </strong>when complete, is the most severe form of CAH. Most cases are due to mutations in the steroidogenic acute regulatory protein (StAR), which increases cholesterol transport from the outer to the inner mitochondrial membrane. StAR is required for normal steroidogenesis in the adrenal cortex and gonads  (<a class="graphic graphic_figure graphicRef56021" href="/d/graphic/56021.html" rel="external">figure 9</a>). Patients typically have severe combined adrenal insufficiency soon after birth, or occasionally later in infancy. Male infants usually have female external genitalia due to lack of testicular androgen production. Female patients occasionally undergo spontaneous partial pubertal development, and one patient has conceived and carried two normal children to term. A nonclassic form of LCAH with isolated cortisol deficiency also exists. (See <a class="local">'Lipoid congenital adrenal hyperplasia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cholesterol side-chain cleavage enzyme (CYP11A1) deficiency</strong> – CYP11A1, encoded by <em>CYP11A1,</em> catalyzes the conversion of cholesterol to pregnenolone in the mitochondria of steroidogenic cells. All patients described with CYP11A1 deficiency had adrenal insufficiency, and the adrenal glands are not enlarged as in most cases of LCAH. (See <a class="local">'Cholesterol side-chain cleavage enzyme (CYP11A1) deficiency'</a> above.)</p><p></p><p class="headingAnchor" id="H618955950"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The views expressed in this topic are those of the author(s) and do not reflect the official views or policy of the United States Government or its components.</p><p>The UpToDate editorial staff acknowledges Wiebke Arlt, MD, DSc, FRCP, FMedSci, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 2000; 21:245.</a></li><li><a class="nounderline abstract_t">Yanase T, Simpson ER, Waterman MR. 17 alpha-hydroxylase/17,20-lyase deficiency: from clinical investigation to molecular definition. Endocr Rev 1991; 12:91.</a></li><li><a class="nounderline abstract_t">Biglieri EG, Herron MA, Brust N. 17-hydroxylation deficiency in man. J Clin Invest 1966; 45:1946.</a></li><li><a class="nounderline abstract_t">Kater CE, Biglieri EG. Disorders of steroid 17 alpha-hydroxylase deficiency. Endocrinol Metab Clin North Am 1994; 23:341.</a></li><li><a class="nounderline abstract_t">Costa-Santos M, Kater CE, Auchus RJ, Brazilian Congenital Adrenal Hyperplasia Multicenter Study Group. Two prevalent CYP17 mutations and genotype-phenotype correlations in 24 Brazilian patients with 17-hydroxylase deficiency. J Clin Endocrinol Metab 2004; 89:49.</a></li><li><a class="nounderline abstract_t">Geller DH, Auchus RJ, Mendonça BB, Miller WL. The genetic and functional basis of isolated 17,20-lyase deficiency. Nat Genet 1997; 17:201.</a></li><li><a class="nounderline abstract_t">Sherbet DP, Tiosano D, Kwist KM, et al. CYP17 mutation E305G causes isolated 17,20-lyase deficiency by selectively altering substrate binding. J Biol Chem 2003; 278:48563.</a></li><li><a class="nounderline abstract_t">Chung BC, Picado-Leonard J, Haniu M, et al. Cytochrome P450c17 (steroid 17 alpha-hydroxylase/17,20 lyase): cloning of human adrenal and testis cDNAs indicates the same gene is expressed in both tissues. Proc Natl Acad Sci U S A 1987; 84:407.</a></li><li><a class="nounderline abstract_t">Moreira AC, Leal AM, Castro M. Characterization of adrenocorticotropin secretion in a patient with 17 alpha-hydroxylase deficiency. J Clin Endocrinol Metab 1990; 71:86.</a></li><li><a class="nounderline abstract_t">Heremans GF, Moolenaar AJ, van Gelderen HH. Female phenotype in a male child due to 17-alpha-hydroxylase deficiency. Arch Dis Child 1976; 51:721.</a></li><li><a class="nounderline abstract_t">Auchus RJ, Lee TC, Miller WL. Cytochrome b5 augments the 17,20-lyase activity of human P450c17 without direct electron transfer. J Biol Chem 1998; 273:3158.</a></li><li><a class="nounderline abstract_t">Kater CE, Biglieri EG, Brust N, et al. The unique patterns of plasma aldosterone and 18-hydroxycorticosterone concentrations in the 17 alpha-hydroxylase deficiency syndrome. J Clin Endocrinol Metab 1982; 55:295.</a></li><li><a class="nounderline abstract_t">Griffing GT, Wilson TE, Holbrook MM, et al. Plasma and urinary 19-nor-deoxycorticosterone in 17 alpha-hydroxylase deficiency syndrome. J Clin Endocrinol Metab 1984; 59:1011.</a></li><li><a class="nounderline abstract_t">Simsek E, Ozdemir I, Lin L, Achermann JC. Isolated 17,20-lyase (desmolase) deficiency in a 46,XX female presenting with delayed puberty. Fertil Steril 2005; 83:1548.</a></li><li><a class="nounderline abstract_t">Auchus RJ. Steroid 17-hydroxylase and 17,20-lyase deficiencies, genetic and pharmacologic. J Steroid Biochem Mol Biol 2017; 165:71.</a></li><li class="breakAll">Auchus RJ, Newell-Price JDC. Enzymes and pathways of human steroidogenesis. In: Endocrinology: Basic Science and Clinical Practice, 8th ed, Robertson RP (Ed), Saunders Elsevier, Philadelphia 2022. Vol 2, p.1449.</li><li><a class="nounderline abstract_t">Kardelen AD, Toksoy G, Baş F, et al. A Rare Cause of Congenital Adrenal Hyperplasia: Clinical and Genetic Findings and Follow-up Characteristics of Six Patients with 17-Hydroxylase Deficiency Including Two Novel Mutations. J Clin Res Pediatr Endocrinol 2018; 10:206.</a></li><li><a class="nounderline abstract_t">Biglieri EG. Mechanisms establishing the mineralocorticoid hormone patterns in the 17 alpha-hydroxylase deficiency syndrome. J Steroid Biochem 1979; 11:653.</a></li><li><a class="nounderline abstract_t">Dean HJ, Shackleton CH, Winter JS. Diagnosis and natural history of 17-hydroxylase deficiency in a newborn male. J Clin Endocrinol Metab 1984; 59:513.</a></li><li><a class="nounderline abstract_t">Morimoto I, Maeda R, Izumi M, et al. An autopsy case of 17 alpha-hydroxylase deficiency with malignant hypertension. J Clin Endocrinol Metab 1983; 56:915.</a></li><li><a class="nounderline abstract_t">Peter M, Sippell WG, Wernze H. Diagnosis and treatment of 17-hydroxylase deficiency. J Steroid Biochem Mol Biol 1993; 45:107.</a></li><li><a class="nounderline abstract_t">Tiosano D, Knopf C, Koren I, et al. Metabolic evidence for impaired 17alpha-hydroxylase activity in a kindred bearing the E305G mutation for isolate 17,20-lyase activity. Eur J Endocrinol 2008; 158:385.</a></li><li><a class="nounderline abstract_t">Martin RM, Lin CJ, Costa EM, et al. P450c17 deficiency in Brazilian patients: biochemical diagnosis through progesterone levels confirmed by CYP17 genotyping. J Clin Endocrinol Metab 2003; 88:5739.</a></li><li><a class="nounderline abstract_t">Flück CE, Tajima T, Pandey AV, et al. Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nat Genet 2004; 36:228.</a></li><li><a class="nounderline abstract_t">Hershkovitz E, Parvari R, Wudy SA, et al. Homozygous mutation G539R in the gene for P450 oxidoreductase in a family previously diagnosed as having 17,20-lyase deficiency. J Clin Endocrinol Metab 2008; 93:3584.</a></li><li><a class="nounderline abstract_t">Arlt W, Walker EA, Draper N, et al. Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study. Lancet 2004; 363:2128.</a></li><li><a class="nounderline abstract_t">Homma K, Hasegawa T, Nagai T, et al. Urine steroid hormone profile analysis in cytochrome P450 oxidoreductase deficiency: implication for the backdoor pathway to dihydrotestosterone. J Clin Endocrinol Metab 2006; 91:2643.</a></li><li><a class="nounderline abstract_t">Winter JS, Couch RM, Muller J, et al. Combined 17-hydroxylase and 17,20-desmolase deficiencies: evidence for synthesis of a defective cytochrome P450c17. J Clin Endocrinol Metab 1989; 68:309.</a></li><li><a class="nounderline abstract_t">Wit JM, van Roermund HP, Oostdijk W, et al. Heterozygotes for 17 alpha-hydroxylase deficiency can be detected with a short ACTH test. Clin Endocrinol (Oxf) 1988; 28:657.</a></li><li><a class="nounderline abstract_t">D'Armiento M, Reda G, Kater C, et al. 17 alpha-hydroxylase deficiency: mineralocorticoid hormone profiles in an affected family. J Clin Endocrinol Metab 1983; 56:697.</a></li><li><a class="nounderline abstract_t">Sparkes RS, Klisak I, Miller WL. Regional mapping of genes encoding human steroidogenic enzymes: P450scc to 15q23-q24, adrenodoxin to 11q22; adrenodoxin reductase to 17q24-q25; and P450c17 to 10q24-q25. DNA Cell Biol 1991; 10:359.</a></li><li><a class="nounderline abstract_t">Kagimoto M, Winter JS, Kagimoto K, et al. Structural characterization of normal and mutant human steroid 17 alpha-hydroxylase genes: molecular basis of one example of combined 17 alpha-hydroxylase/17,20 lyase deficiency. Mol Endocrinol 1988; 2:564.</a></li><li><a class="nounderline abstract_t">Yanase T, Sanders D, Shibata A, et al. Combined 17 alpha-hydroxylase/17,20-lyase deficiency due to a 7-basepair duplication in the N-terminal region of the cytochrome P45017 alpha (CYP17) gene. J Clin Endocrinol Metab 1990; 70:1325.</a></li><li><a class="nounderline abstract_t">Yanase T, Kagimoto M, Suzuki S, et al. Deletion of a phenylalanine in the N-terminal region of human cytochrome P-450(17 alpha) results in partial combined 17 alpha-hydroxylase/17,20-lyase deficiency. J Biol Chem 1989; 264:18076.</a></li><li><a class="nounderline abstract_t">Fardella CE, Zhang LH, Mahachoklertwattana P, et al. Deletion of amino acids Asp487-Ser488-Phe489 in human cytochrome P450c17 causes severe 17 alpha-hydroxylase deficiency. J Clin Endocrinol Metab 1993; 77:489.</a></li><li><a class="nounderline abstract_t">Biason A, Mantero F, Scaroni C, et al. Deletion within the CYP17 gene together with insertion of foreign DNA is the cause of combined complete 17 alpha-hydroxylase/17,20-lyase deficiency in an Italian patient. Mol Endocrinol 1991; 5:2037.</a></li><li><a class="nounderline abstract_t">Rumsby G, Skinner C, Lee HA, Honour JW. Combined 17 alpha-hydroxylase/17,20-lyase deficiency caused by heterozygous stop codons in the cytochrome P450 17 alpha-hydroxylase gene. Clin Endocrinol (Oxf) 1993; 39:483.</a></li><li><a class="nounderline abstract_t">Yanase T, Kagimoto M, Matsui N, et al. Combined 17 alpha-hydroxylase/17,20-lyase deficiency due to a stop codon in the N-terminal region of 17 alpha-hydroxylase cytochrome P-450. Mol Cell Endocrinol 1988; 59:249.</a></li><li><a class="nounderline abstract_t">Lin D, Black SM, Nagahama Y, Miller WL. Steroid 17 alpha-hydroxylase and 17,20-lyase activities of P450c17: contributions of serine106 and P450 reductase. Endocrinology 1993; 132:2498.</a></li><li><a class="nounderline abstract_t">Monno S, Ogawa H, Date T, et al. Mutation of histidine 373 to leucine in cytochrome P450c17 causes 17 alpha-hydroxylase deficiency. J Biol Chem 1993; 268:25811.</a></li><li><a class="nounderline abstract_t">Costa-Santos M, Kater CE, Dias EP, Auchus RJ. Two intronic mutations cause 17-hydroxylase deficiency by disrupting splice acceptor sites: direct demonstration of aberrant splicing and absent enzyme activity by expression of the entire CYP17 gene in HEK-293 cells. J Clin Endocrinol Metab 2004; 89:43.</a></li><li><a class="nounderline abstract_t">Yanase T, Waterman MR, Zachmann M, et al. Molecular basis of apparent isolated 17,20-lyase deficiency: compound heterozygous mutations in the C-terminal region (Arg(496)----Cys, Gln(461)----Stop) actually cause combined 17 alpha-hydroxylase/17,20-lyase deficiency. Biochim Biophys Acta 1992; 1139:275.</a></li><li><a class="nounderline abstract_t">Yamaguchi H, Nakazato M, Miyazato M, et al. A 5'-splice site mutation in the cytochrome P450 steroid 17alpha-hydroxylase gene in 17alpha-hydroxylase deficiency. J Clin Endocrinol Metab 1997; 82:1934.</a></li><li><a class="nounderline abstract_t">Hegesh E, Hegesh J, Kaftory A. Congenital methemoglobinemia with a deficiency of cytochrome b5. N Engl J Med 1986; 314:757.</a></li><li><a class="nounderline abstract_t">Giordano SJ, Kaftory A, Steggles AW. A splicing mutation in the cytochrome b5 gene from a patient with congenital methemoglobinemia and pseudohermaphrodism. Hum Genet 1994; 93:568.</a></li><li><a class="nounderline abstract_t">Brooke AM, Taylor NF, Shepherd JH, et al. A novel point mutation in P450c17 (CYP17) causing combined 17alpha-hydroxylase/17,20-lyase deficiency. J Clin Endocrinol Metab 2006; 91:2428.</a></li><li><a class="nounderline abstract_t">Ergun-Longmire B, Auchus R, Papari-Zareei M, et al. Two novel mutations found in a patient with 17alpha-hydroxylase enzyme deficiency. J Clin Endocrinol Metab 2006; 91:4179.</a></li><li><a class="nounderline abstract_t">Turan S, Bereket A, Guran T, et al. Puberty in a case with novel 17-hydroxylase mutation and the putative role of estrogen in development of pubic hair. Eur J Endocrinol 2009; 160:325.</a></li><li><a class="nounderline abstract_t">Wu C, Fan S, Qian Y, et al. 17α-HYDROXYLASE/17, 20-LYASE DEFICIENCY: CLINICAL AND MOLECULAR CHARACTERIZATION OF EIGHT CHINESE PATIENTS. Endocr Pract 2017; 23:576.</a></li><li><a class="nounderline abstract_t">Imai T, Globerman H, Gertner JM, et al. Expression and purification of functional human 17 alpha-hydroxylase/17,20-lyase (P450c17) in Escherichia coli. Use of this system for study of a novel form of combined 17 alpha-hydroxylase/17,20-lyase deficiency. J Biol Chem 1993; 268:19681.</a></li><li><a class="nounderline abstract_t">Gupta MK, Geller DH, Auchus RJ. Pitfalls in characterizing P450c17 mutations associated with isolated 17,20-lyase deficiency. J Clin Endocrinol Metab 2001; 86:4416.</a></li><li><a class="nounderline abstract_t">Geller DH, Auchus RJ, Miller WL. P450c17 mutations R347H and R358Q selectively disrupt 17,20-lyase activity by disrupting interactions with P450 oxidoreductase and cytochrome b5. Mol Endocrinol 1999; 13:167.</a></li><li><a class="nounderline abstract_t">Rovner DR, Conn JW, Cohen EL, et al. 17 alpha-Hydroxylase deficiency. A combination of hydroxylation defect and reversible blockade in aldosterone biosynthesis. Acta Endocrinol (Copenh) 1979; 90:490.</a></li><li><a class="nounderline abstract_t">Bianchi PH, Gouveia GR, Costa EM, et al. Successful Live Birth in a Woman With 17α-Hydroxylase Deficiency Through IVF Frozen-Thawed Embryo Transfer. J Clin Endocrinol Metab 2016; 101:345.</a></li><li><a class="nounderline abstract_t">BONGIOVANNI AM. The adrenogenital syndrome with deficiency of 3 beta-hydroxysteroid dehydrogenase. J Clin Invest 1962; 41:2086.</a></li><li><a class="nounderline abstract_t">Moisan AM, Ricketts ML, Tardy V, et al. New insight into the molecular basis of 3beta-hydroxysteroid dehydrogenase deficiency: identification of eight mutations in the HSD3B2 gene eleven patients from seven new families and comparison of the functional properties of twenty-five mutant enzymes. J Clin Endocrinol Metab 1999; 84:4410.</a></li><li><a class="nounderline abstract_t">Lachance Y, Luu-The V, Labrie C, et al. Characterization of human 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase gene and its expression in mammalian cells. J Biol Chem 1990; 265:20469.</a></li><li><a class="nounderline abstract_t">Lutfallah C, Wang W, Mason JI, et al. Newly proposed hormonal criteria via genotypic proof for type II 3beta-hydroxysteroid dehydrogenase deficiency. J Clin Endocrinol Metab 2002; 87:2611.</a></li><li><a class="nounderline abstract_t">Mermejo LM, Elias LL, Marui S, et al. Refining hormonal diagnosis of type II 3beta-hydroxysteroid dehydrogenase deficiency in patients with premature pubarche and hirsutism based on HSD3B2 genotyping. J Clin Endocrinol Metab 2005; 90:1287.</a></li><li><a class="nounderline abstract_t">Simard J, Rheaume E, Mebarki F, et al. Molecular basis of human 3 beta-hydroxysteroid dehydrogenase deficiency. J Steroid Biochem Mol Biol 1995; 53:127.</a></li><li><a class="nounderline abstract_t">Rhéaume E, Lachance Y, Zhao HF, et al. Structure and expression of a new complementary DNA encoding the almost exclusive 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase in human adrenals and gonads. Mol Endocrinol 1991; 5:1147.</a></li><li><a class="nounderline abstract_t">Rhéaume E, Simard J, Morel Y, et al. Congenital adrenal hyperplasia due to point mutations in the type II 3 beta-hydroxysteroid dehydrogenase gene. Nat Genet 1992; 1:239.</a></li><li><a class="nounderline abstract_t">Simard J, Rhéaume E, Leblanc JF, et al. Congenital adrenal hyperplasia caused by a novel homozygous frameshift mutation 273 delta AA in type II 3 beta-hydroxysteroid dehydrogenase gene (HSD3B2) in three male patients of Afghan/Pakistani origin. Hum Mol Genet 1994; 3:327.</a></li><li><a class="nounderline abstract_t">Rhéaume E, Sanchez R, Mébarki F, et al. Identification and characterization of the G15D mutation found in a male patient with 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) deficiency: alteration of the putative NAD-binding domain of type II 3 beta-HSD. Biochemistry 1995; 34:2893.</a></li><li><a class="nounderline abstract_t">Simard J, Rhéaume E, Sanchez R, et al. Molecular basis of congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency. Mol Endocrinol 1993; 7:716.</a></li><li><a class="nounderline abstract_t">Rhéaume E, Sanchez R, Simard J, et al. Molecular basis of congenital adrenal hyperplasia in two siblings with classical nonsalt-losing 3 beta-hydroxysteroid dehydrogenase deficiency. J Clin Endocrinol Metab 1994; 79:1012.</a></li><li><a class="nounderline abstract_t">Sanchez R, Rhéaume E, Laflamme N, et al. Detection and functional characterization of the novel missense mutation Y254D in type II 3 beta-hydroxysteroid dehydrogenase (3 beta HSD) gene of a female patient with nonsalt-losing 3 beta HSD deficiency. J Clin Endocrinol Metab 1994; 78:561.</a></li><li><a class="nounderline abstract_t">Cara JF, Moshang T Jr, Bongiovanni AM, Marx BS. Elevated 17-hydroxyprogesterone and testosterone in a newborn with 3-beta-hydroxysteroid dehydrogenase deficiency. N Engl J Med 1985; 313:618.</a></li><li><a class="nounderline abstract_t">BONGIOVANNI AM, ROOT AW. The adrenogenital syndrome. N Engl J Med 1963; 268:1283.</a></li><li><a class="nounderline abstract_t">Guran T, Kara C, Yildiz M, et al. Revisiting Classical 3β-hydroxysteroid Dehydrogenase 2 Deficiency: Lessons from 31 Pediatric Cases. J Clin Endocrinol Metab 2020; 105.</a></li><li><a class="nounderline abstract_t">Pang SY, Lerner AJ, Stoner E, et al. Late-onset adrenal steroid 3 beta-hydroxysteroid dehydrogenase deficiency. I. A cause of hirsutism in pubertal and postpubertal women. J Clin Endocrinol Metab 1985; 60:428.</a></li><li><a class="nounderline abstract_t">Azziz R, Bradley EL Jr, Potter HD, Boots LR. 3 beta-hydroxysteroid dehydrogenase deficiency in hyperandrogenism. Am J Obstet Gynecol 1993; 168:889.</a></li><li><a class="nounderline abstract_t">Pang S, Carbunaru G, Haider A, et al. Carriers for type II 3beta-hydroxysteroid dehydrogenase (HSD3B2) deficiency can only be identified by HSD3B2 genotype study and not by hormone test. Clin Endocrinol (Oxf) 2003; 58:323.</a></li><li><a class="nounderline abstract_t">Codner E, Okuma C, Iñiguez G, et al. Molecular study of the 3 beta-hydroxysteroid dehydrogenase gene type II in patients with hypospadias. J Clin Endocrinol Metab 2004; 89:957.</a></li><li><a class="nounderline abstract_t">Pang S, Levine LS, Stoner E, et al. Nonsalt-losing congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency with normal glomerulosa function. J Clin Endocrinol Metab 1983; 56:808.</a></li><li><a class="nounderline abstract_t">Rosenfield RL, Rich BH, Wolfsdorf JI, et al. Pubertal presentation of congenital delta 5-3 beta-hydroxysteroid dehydrogenase deficiency. J Clin Endocrinol Metab 1980; 51:345.</a></li><li><a class="nounderline abstract_t">Marui S, Castro M, Latronico AC, et al. Mutations in the type II 3beta-hydroxysteroid dehydrogenase (HSD3B2) gene can cause premature pubarche in girls. Clin Endocrinol (Oxf) 2000; 52:67.</a></li><li><a class="nounderline abstract_t">White PC, Curnow KM, Pascoe L. Disorders of steroid 11 beta-hydroxylase isozymes. Endocr Rev 1994; 15:421.</a></li><li><a class="nounderline abstract_t">Rösler A, Leiberman E, Cohen T. High frequency of congenital adrenal hyperplasia (classic 11 beta-hydroxylase deficiency) among Jews from Morocco. Am J Med Genet 1992; 42:827.</a></li><li><a class="nounderline abstract_t">White PC, Dupont J, New MI, et al. A mutation in CYP11B1 (Arg-448----His) associated with steroid 11 beta-hydroxylase deficiency in Jews of Moroccan origin. J Clin Invest 1991; 87:1664.</a></li><li><a class="nounderline abstract_t">Zachmann M, Tassinari D, Prader A. Clinical and biochemical variability of congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency. A study of 25 patients. J Clin Endocrinol Metab 1983; 56:222.</a></li><li><a class="nounderline abstract_t">de Simone G, Tommaselli AP, Rossi R, et al. Partial deficiency of adrenal 11-hydroxylase. A possible cause of primary hypertension. Hypertension 1985; 7:204.</a></li><li><a class="nounderline abstract_t">Rösler A, Leiberman E, Sack J, et al. Clinical variability of congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency. Horm Res 1982; 16:133.</a></li><li><a class="nounderline abstract_t">Zhu YS, Cordero JJ, Can S, et al. Mutations in CYP11B1 gene: phenotype-genotype correlations. Am J Med Genet A 2003; 122A:193.</a></li><li><a class="nounderline abstract_t">Hochberg Z, Benderly A, Kahana L, Zadik Z. Requirement of mineralocorticoid in congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency. J Clin Endocrinol Metab 1986; 63:36.</a></li><li><a class="nounderline abstract_t">Zadik Z, Kahana L, Kaufman H, et al. Salt loss in hypertensive form of congenital adrenal hyperplasia (11-beta-hydroxylase deficiency). J Clin Endocrinol Metab 1984; 58:384.</a></li><li><a class="nounderline abstract_t">Holcombe JH, Keenan BS, Nichols BL, et al. Neonatal salt loss in the hypertensive form of congenital adrenal hyperplasia. Pediatrics 1980; 65:777.</a></li><li><a class="nounderline abstract_t">Storr HL, Barwick TD, Snodgrass GA, et al. Hyperplasia of adrenal rest tissue causing a retroperitoneal mass in a child with 11 beta-hydroxylase deficiency. Horm Res 2003; 60:99.</a></li><li><a class="nounderline abstract_t">Ghazi AA, Hadayegh F, Khakpour G, et al. Bilateral testicular enlargement due to adrenal remnant in a patient with C11 hydroxylase deficiency congenital adrenal hyperplasia. J Endocrinol Invest 2003; 26:84.</a></li><li><a class="nounderline abstract_t">Cathelineau G, Brerault JL, Fiet J, et al. Adrenocortical 11 beta-hydroxylation defect in adult women with postmenarchial onset of symptoms. J Clin Endocrinol Metab 1980; 51:287.</a></li><li><a class="nounderline abstract_t">Lucky AW, Rosenfield RL, McGuire J, et al. Adrenal androgen hyperresponsiveness to adrenocorticotropin in women with acne and/or hirsutism: adrenal enzyme defects and exaggerated adrenarche. J Clin Endocrinol Metab 1986; 62:840.</a></li><li><a class="nounderline abstract_t">Joehrer K, Geley S, Strasser-Wozak EM, et al. CYP11B1 mutations causing non-classic adrenal hyperplasia due to 11 beta-hydroxylase deficiency. Hum Mol Genet 1997; 6:1829.</a></li><li><a class="nounderline abstract_t">Reisch N, Högler W, Parajes S, et al. A diagnosis not to be missed: nonclassic steroid 11β-hydroxylase deficiency presenting with premature adrenarche and hirsutism. J Clin Endocrinol Metab 2013; 98:E1620.</a></li><li><a class="nounderline abstract_t">Yildiz M, Isik E, Abali ZY, et al. Clinical and Hormonal Profiles Correlate With Molecular Characteristics in Patients With 11β-Hydroxylase Deficiency. J Clin Endocrinol Metab 2021; 106:e3714.</a></li><li><a class="nounderline abstract_t">GREEN OC, MIGEON CJ, WILKINS L. Urinary steroids in the hypertensive form of congenital adrenal hyperplasia. J Clin Endocrinol Metab 1960; 20:929.</a></li><li><a class="nounderline abstract_t">Lashansky G, Saenger P, Dimartino-Nardi J, et al. Normative data for the steroidogenic response of mineralocorticoids and their precursors to adrenocorticotropin in a healthy pediatric population. J Clin Endocrinol Metab 1992; 75:1491.</a></li><li><a class="nounderline abstract_t">Lashansky G, Saenger P, Fishman K, et al. Normative data for adrenal steroidogenesis in a healthy pediatric population: age- and sex-related changes after adrenocorticotropin stimulation. J Clin Endocrinol Metab 1991; 73:674.</a></li><li><a class="nounderline abstract_t">DYRENFURTH I, SYBULSKI S, NOTCHEV V, et al. Urinary corticosteroid excretion patterns in patients with adrenocortical dysfunction. J Clin Endocrinol Metab 1958; 18:391.</a></li><li><a class="nounderline abstract_t">GABRILOVE JL, SHARMA DC, DORFMAN RI. ADRENOCORTICAL 11-BETA-HYDROXYLASE DEFICIENCY AND VIRILISM FIRST MANIFEST IN THE ADULT WOMEN. N Engl J Med 1965; 272:1189.</a></li><li><a class="nounderline abstract_t">Auchus RJ. The classic and nonclassic concenital adrenal hyperplasias. Endocr Pract 2015; 21:383.</a></li><li><a class="nounderline abstract_t">Pang S, Levine LS, Lorenzen F, et al. Hormonal studies in obligate heterozygotes and siblings of patients with 11 beta-hydroxylase deficiency congenital adrenal hyperplasia. J Clin Endocrinol Metab 1980; 50:586.</a></li><li><a class="nounderline abstract_t">Curnow KM, Slutsker L, Vitek J, et al. Mutations in the CYP11B1 gene causing congenital adrenal hyperplasia and hypertension cluster in exons 6, 7, and 8. Proc Natl Acad Sci U S A 1993; 90:4552.</a></li><li><a class="nounderline abstract_t">Grigorescu Sido A, Weber MM, Grigorescu Sido P, et al. 21-Hydroxylase and 11beta-hydroxylase mutations in Romanian patients with classic congenital adrenal hyperplasia. J Clin Endocrinol Metab 2005; 90:5769.</a></li><li><a class="nounderline abstract_t">Krone N, Riepe FG, Götze D, et al. Congenital adrenal hyperplasia due to 11-hydroxylase deficiency: functional characterization of two novel point mutations and a three-base pair deletion in the CYP11B1 gene. J Clin Endocrinol Metab 2005; 90:3724.</a></li><li><a class="nounderline abstract_t">Helmberg A, Ausserer B, Kofler R. Frame shift by insertion of 2 basepairs in codon 394 of CYP11B1 causes congenital adrenal hyperplasia due to steroid 11 beta-hydroxylase deficiency. J Clin Endocrinol Metab 1992; 75:1278.</a></li><li><a class="nounderline abstract_t">Naiki Y, Kawamoto T, Mitsuuchi Y, et al. A nonsense mutation (TGG [Trp116]--&gt;TAG [Stop]) in CYP11B1 causes steroid 11 beta-hydroxylase deficiency. J Clin Endocrinol Metab 1993; 77:1677.</a></li><li><a class="nounderline abstract_t">Kuribayashi I, Massa G, van den Tooren-de Groot HK, et al. A novel nonsense mutation in the Cyp11B1 gene from a subject with the steroid 11beta-hydroxylase form of congenital adrenal hyperplasia. Endocr Res 2003; 29:377.</a></li><li><a class="nounderline abstract_t">Portrat S, Mulatero P, Curnow KM, et al. Deletion hybrid genes, due to unequal crossing over between CYP11B1 (11beta-hydroxylase) and CYP11B2(aldosterone synthase) cause steroid 11beta-hydroxylase deficiency and congenital adrenal hyperplasia. J Clin Endocrinol Metab 2001; 86:3197.</a></li><li><a class="nounderline abstract_t">Hampf M, Dao NT, Hoan NT, Bernhardt R. Unequal crossing-over between aldosterone synthase and 11beta-hydroxylase genes causes congenital adrenal hyperplasia. J Clin Endocrinol Metab 2001; 86:4445.</a></li><li><a class="nounderline abstract_t">Simm PJ, Zacharin MR. Successful pregnancy in a patient with severe 11-beta-hydroxylase deficiency and novel mutations in CYP11B1 gene. Horm Res 2007; 68:294.</a></li><li><a class="nounderline abstract_t">Rösler A, Leiberman E, Rosenmann A, et al. Prenatal diagnosis of 11beta-hydroxylase deficiency congenital adrenal hyperplasia. J Clin Endocrinol Metab 1979; 49:546.</a></li><li><a class="nounderline abstract_t">Cerame BI, Newfield RS, Pascoe L, et al. Prenatal diagnosis and treatment of 11beta-hydroxylase deficiency congenital adrenal hyperplasia resulting in normal female genitalia. J Clin Endocrinol Metab 1999; 84:3129.</a></li><li><a class="nounderline abstract_t">Peterson RE, Imperato-McGinley J, Gautier T, Shackleton C. Male pseudohermaphroditism due to multiple defects in steroid-biosynthetic microsomal mixed-function oxidases. A new variant of congenital adrenal hyperplasia. N Engl J Med 1985; 313:1182.</a></li><li><a class="nounderline abstract_t">Shackleton C, Marcos J, Malunowicz EM, et al. Biochemical diagnosis of Antley-Bixler syndrome by steroid analysis. Am J Med Genet A 2004; 128A:223.</a></li><li><a class="nounderline abstract_t">Adachi M, Asakura Y, Tachibana K, Shackleton C. Abnormal steroidogenesis in three patients with Antley-Bixler syndrome: apparent decreased activity of 17alpha-hydroxylase, 17,20-lyase and 21-hydroxylase. Pediatr Int 2004; 46:583.</a></li><li><a class="nounderline abstract_t">Fukami M, Nishimura G, Homma K, et al. Cytochrome P450 oxidoreductase deficiency: identification and characterization of biallelic mutations and genotype-phenotype correlations in 35 Japanese patients. J Clin Endocrinol Metab 2009; 94:1723.</a></li><li><a class="nounderline abstract_t">Huang N, Pandey AV, Agrawal V, et al. Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis. Am J Hum Genet 2005; 76:729.</a></li><li><a class="nounderline abstract_t">Williamson L, Arlt W, Shackleton C, et al. Linking Antley-Bixler syndrome and congenital adrenal hyperplasia: a novel case of P450 oxidoreductase deficiency. Am J Med Genet A 2006; 140A:1797.</a></li><li><a class="nounderline abstract_t">Wudy SA, Hartmann MF, Draper N, et al. A male twin infant with skull deformity and elevated neonatal 17-hydroxyprogesterone: a prismatic case of P450 oxidoreductase deficiency. Endocr Res 2004; 30:957.</a></li><li><a class="nounderline abstract_t">Fukami M, Hasegawa T, Horikawa R, et al. Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis. Pediatr Res 2006; 59:276.</a></li><li><a class="nounderline abstract_t">Antley R, Bixler D. Trapezoidocephaly, midfacial hypoplasia and cartilage abnormalities with multiple synostoses and skeletal fractures. Birth Defects Orig Artic Ser 1975; 11:397.</a></li><li><a class="nounderline abstract_t">Dhir V, Ivison HE, Krone N, et al. Differential inhibition of CYP17A1 and CYP21A2 activities by the P450 oxidoreductase mutant A287P. Mol Endocrinol 2007; 21:1958.</a></li><li><a class="nounderline abstract_t">Pandey AV, Kempná P, Hofer G, et al. Modulation of human CYP19A1 activity by mutant NADPH P450 oxidoreductase. Mol Endocrinol 2007; 21:2579.</a></li><li><a class="nounderline abstract_t">Fukami M, Horikawa R, Nagai T, et al. Cytochrome P450 oxidoreductase gene mutations and Antley-Bixler syndrome with abnormal genitalia and/or impaired steroidogenesis: molecular and clinical studies in 10 patients. J Clin Endocrinol Metab 2005; 90:414.</a></li><li><a class="nounderline abstract_t">Kelley RI, Kratz LE, Glaser RL, et al. Abnormal sterol metabolism in a patient with Antley-Bixler syndrome and ambiguous genitalia. Am J Med Genet 2002; 110:95.</a></li><li><a class="nounderline abstract_t">Mann RK, Beachy PA. Novel lipid modifications of secreted protein signals. Annu Rev Biochem 2004; 73:891.</a></li><li><a class="nounderline abstract_t">Aleck KA, Bartley DL. Multiple malformation syndrome following fluconazole use in pregnancy: report of an additional patient. Am J Med Genet 1997; 72:253.</a></li><li><a class="nounderline abstract_t">Pursley TJ, Blomquist IK, Abraham J, et al. Fluconazole-induced congenital anomalies in three infants. Clin Infect Dis 1996; 22:336.</a></li><li><a class="nounderline abstract_t">Aguilar A, Wu S, De Luca F. P450 oxidoreductase expressed in rat chondrocytes modulates chondrogenesis via cholesterol- and Indian Hedgehog-dependent mechanisms. Endocrinology 2009; 150:2732.</a></li><li><a class="nounderline abstract_t">Agrawal V, Huang N, Miller WL. Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19. Pharmacogenet Genomics 2008; 18:569.</a></li><li><a class="nounderline abstract_t">Hart SN, Li Y, Nakamoto K, et al. Novel SNPs in cytochrome P450 oxidoreductase. Drug Metab Pharmacokinet 2007; 22:322.</a></li><li><a class="nounderline abstract_t">Hart SN, Zhong XB. P450 oxidoreductase: genetic polymorphisms and implications for drug metabolism and toxicity. Expert Opin Drug Metab Toxicol 2008; 4:439.</a></li><li><a class="nounderline abstract_t">Hart SN, Wang S, Nakamoto K, et al. Genetic polymorphisms in cytochrome P450 oxidoreductase influence microsomal P450-catalyzed drug metabolism. Pharmacogenet Genomics 2008; 18:11.</a></li><li><a class="nounderline abstract_t">Huang N, Agrawal V, Giacomini KM, Miller WL. Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations. Proc Natl Acad Sci U S A 2008; 105:1733.</a></li><li><a class="nounderline abstract_t">Kranendonk M, Marohnic CC, Panda SP, et al. Impairment of human CYP1A2-mediated xenobiotic metabolism by Antley-Bixler syndrome variants of cytochrome P450 oxidoreductase. Arch Biochem Biophys 2008; 475:93.</a></li><li><a class="nounderline abstract_t">Cragun DL, Trumpy SK, Shackleton CH, et al. Undetectable maternal serum uE3 and postnatal abnormal sterol and steroid metabolism in Antley-Bixler syndrome. Am J Med Genet A 2004; 129A:1.</a></li><li><a class="nounderline abstract_t">Shackleton C, Marcos J, Arlt W, Hauffa BP. Prenatal diagnosis of P450 oxidoreductase deficiency (ORD): a disorder causing low pregnancy estriol, maternal and fetal virilization, and the Antley-Bixler syndrome phenotype. Am J Med Genet A 2004; 129A:105.</a></li><li><a class="nounderline abstract_t">Chun K, Siegel-Bartelt J, Chitayat D, et al. FGFR2 mutation associated with clinical manifestations consistent with Antley-Bixler syndrome. Am J Med Genet 1998; 77:219.</a></li><li><a class="nounderline abstract_t">Reardon W, Smith A, Honour JW, et al. Evidence for digenic inheritance in some cases of Antley-Bixler syndrome? J Med Genet 2000; 37:26.</a></li><li><a class="nounderline abstract_t">Tsai FJ, Wu JY, Yang CF, Tsai CH. Further evidence that fibroblast growth factor receptor 2 mutations cause Antley-Bixler syndrome. Acta Paediatr 2001; 90:595.</a></li><li><a class="nounderline abstract_t">Adachi M, Asakura Y, Matsuo M, et al. POR R457H is a global founder mutation causing Antley-Bixler syndrome with autosomal recessive trait. Am J Med Genet A 2006; 140:633.</a></li><li><a class="nounderline abstract_t">Shackleton C, Malunowicz E. Apparent pregnene hydroxylation deficiency (APHD): seeking the parentage of an orphan metabolome. Steroids 2003; 68:707.</a></li><li><a class="nounderline abstract_t">Tomlinson JW, Walker EA, Bujalska IJ, et al. 11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev 2004; 25:831.</a></li><li><a class="nounderline abstract_t">Biason-Lauber A, Suter SL, Shackleton CH, Zachmann M. Apparent cortisone reductase deficiency: a rare cause of hyperandrogenemia and hypercortisolism. Horm Res 2000; 53:260.</a></li><li><a class="nounderline abstract_t">Draper N, Walker EA, Bujalska IJ, et al. Mutations in the genes encoding 11beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency. Nat Genet 2003; 34:434.</a></li><li><a class="nounderline abstract_t">Jamieson A, Wallace AM, Andrew R, et al. Apparent cortisone reductase deficiency: a functional defect in 11beta-hydroxysteroid dehydrogenase type 1. J Clin Endocrinol Metab 1999; 84:3570.</a></li><li><a class="nounderline abstract_t">Lavery GG, Walker EA, Tiganescu A, et al. Steroid biomarkers and genetic studies reveal inactivating mutations in hexose-6-phosphate dehydrogenase in patients with cortisone reductase deficiency. J Clin Endocrinol Metab 2008; 93:3827.</a></li><li><a class="nounderline abstract_t">Małunowicz EM, Romer TE, Urban M, Bossowski A. 11beta-hydroxysteroid dehydrogenase type 1 deficiency ('apparent cortisone reductase deficiency') in a 6-year-old boy. Horm Res 2003; 59:205.</a></li><li><a class="nounderline abstract_t">Nikkilä H, Tannin GM, New MI, et al. Defects in the HSD11 gene encoding 11 beta-hydroxysteroid dehydrogenase are not found in patients with apparent mineralocorticoid excess or 11-oxoreductase deficiency. J Clin Endocrinol Metab 1993; 77:687.</a></li><li><a class="nounderline abstract_t">Phillipov G, Palermo M, Shackleton CH. Apparent cortisone reductase deficiency: a unique form of hypercortisolism. J Clin Endocrinol Metab 1996; 81:3855.</a></li><li><a class="nounderline abstract_t">Mason PJ, Stevens D, Diez A, et al. Human hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase) encoded at 1p36: coding sequence and expression. Blood Cells Mol Dis 1999; 25:30.</a></li><li><a class="nounderline abstract_t">Draper N, Powell BL, Franks S, et al. Variants implicated in cortisone reductase deficiency do not contribute to susceptibility to common forms of polycystic ovary syndrome. Clin Endocrinol (Oxf) 2006; 65:64.</a></li><li><a class="nounderline abstract_t">Smit P, Dekker MJ, de Jong FJ, et al. Lack of Association of the 11beta-hydroxysteroid dehydrogenase type 1 gene 83,557insA and hexose-6-phosphate dehydrogenase gene R453Q polymorphisms with body composition, adrenal androgen production, blood pressure, glucose metabolism, and dementia. J Clin Endocrinol Metab 2007; 92:359.</a></li><li><a class="nounderline abstract_t">Faiyaz ul Haque M, King LM, Krakow D, et al. Mutations in orthologous genes in human spondyloepimetaphyseal dysplasia and the brachymorphic mouse. Nat Genet 1998; 20:157.</a></li><li><a class="nounderline abstract_t">Noordam C, Dhir V, McNelis JC, et al. Inactivating PAPSS2 mutations in a patient with premature pubarche. N Engl J Med 2009; 360:2310.</a></li><li><a class="nounderline abstract_t">Oostdijk W, Idkowiak J, Mueller JW, et al. PAPSS2 deficiency causes androgen excess via impaired DHEA sulfation--in vitro and in vivo studies in a family harboring two novel PAPSS2 mutations. J Clin Endocrinol Metab 2015; 100:E672.</a></li><li><a class="nounderline abstract_t">Strott CA. Sulfonation and molecular action. Endocr Rev 2002; 23:703.</a></li><li><a class="nounderline abstract_t">Ahmad M, Faiyaz Ul Haque M, Ahmad W, et al. Distinct, autosomal recessive form of spondyloepimetaphyseal dysplasia segregating in an inbred Pakistani kindred. Am J Med Genet 1998; 78:468.</a></li><li><a class="nounderline abstract_t">Sugawara T, Holt JA, Driscoll D, et al. Human steroidogenic acute regulatory protein: functional activity in COS-1 cells, tissue-specific expression, and mapping of the structural gene to 8p11.2 and a pseudogene to chromosome 13. Proc Natl Acad Sci U S A 1995; 92:4778.</a></li><li><a class="nounderline abstract_t">Lin D, Sugawara T, Strauss JF 3rd, et al. Role of steroidogenic acute regulatory protein in adrenal and gonadal steroidogenesis. Science 1995; 267:1828.</a></li><li><a class="nounderline abstract_t">Clark BJ, Wells J, King SR, Stocco DM. The purification, cloning, and expression of a novel luteinizing hormone-induced mitochondrial protein in MA-10 mouse Leydig tumor cells. Characterization of the steroidogenic acute regulatory protein (StAR). J Biol Chem 1994; 269:28314.</a></li><li><a class="nounderline abstract_t">Stocco DM, Ascoli M. The use of genetic manipulation of MA-10 Leydig tumor cells to demonstrate the role of mitochondrial proteins in the acute regulation of steroidogenesis. Endocrinology 1993; 132:959.</a></li><li><a class="nounderline abstract_t">Stocco DM, Sodeman TC. The 30-kDa mitochondrial proteins induced by hormone stimulation in MA-10 mouse Leydig tumor cells are processed from larger precursors. J Biol Chem 1991; 266:19731.</a></li><li><a class="nounderline abstract_t">Bose HS, Sugawara T, Strauss JF 3rd, et al. The pathophysiology and genetics of congenital lipoid adrenal hyperplasia. N Engl J Med 1996; 335:1870.</a></li><li><a class="nounderline abstract_t">Katsumata N, Kawada Y, Yamamoto Y, et al. A novel compound heterozygous mutation in the steroidogenic acute regulatory protein gene in a patient with congenital lipoid adrenal hyperplasia. J Clin Endocrinol Metab 1999; 84:3983.</a></li><li><a class="nounderline abstract_t">González AA, Reyes ML, Carvajal CA, et al. Congenital lipoid adrenal hyperplasia caused by a novel splicing mutation in the gene for the steroidogenic acute regulatory protein. J Clin Endocrinol Metab 2004; 89:946.</a></li><li><a class="nounderline abstract_t">Fujieda K, Okuhara K, Abe S, et al. Molecular pathogenesis of lipoid adrenal hyperplasia and adrenal hypoplasia congenita. J Steroid Biochem Mol Biol 2003; 85:483.</a></li><li><a class="nounderline abstract_t">Miller WL. Disorders in the initial steps of steroid hormone synthesis. J Steroid Biochem Mol Biol 2017; 165:18.</a></li><li><a class="nounderline abstract_t">Bose HS, Pescovitz OH, Miller WL. Spontaneous feminization in a 46,XX female patient with congenital lipoid adrenal hyperplasia due to a homozygous frameshift mutation in the steroidogenic acute regulatory protein. J Clin Endocrinol Metab 1997; 82:1511.</a></li><li><a class="nounderline abstract_t">Baker BY, Lin L, Kim CJ, et al. Nonclassic congenital lipoid adrenal hyperplasia: a new disorder of the steroidogenic acute regulatory protein with very late presentation and normal male genitalia. J Clin Endocrinol Metab 2006; 91:4781.</a></li><li><a class="nounderline abstract_t">Sahakitrungruang T, Soccio RE, Lang-Muritano M, et al. Clinical, genetic, and functional characterization of four patients carrying partial loss-of-function mutations in the steroidogenic acute regulatory protein (StAR). J Clin Endocrinol Metab 2010; 95:3352.</a></li><li><a class="nounderline abstract_t">Gassner HL, Toppari J, Quinteiro González S, Miller WL. Near-miss apparent SIDS from adrenal crisis. J Pediatr 2004; 145:178.</a></li><li><a class="nounderline abstract_t">Fujieda K, Tajima T, Nakae J, et al. Spontaneous puberty in 46,XX subjects with congenital lipoid adrenal hyperplasia. Ovarian steroidogenesis is spared to some extent despite inactivating mutations in the steroidogenic acute regulatory protein (StAR) gene. J Clin Invest 1997; 99:1265.</a></li><li><a class="nounderline abstract_t">Tajima T, Fujieda K, Kouda N, et al. Heterozygous mutation in the cholesterol side chain cleavage enzyme (p450scc) gene in a patient with 46,XY sex reversal and adrenal insufficiency. J Clin Endocrinol Metab 2001; 86:3820.</a></li><li><a class="nounderline abstract_t">Achermann JC, Ito M, Ito M, et al. A mutation in the gene encoding steroidogenic factor-1 causes XY sex reversal and adrenal failure in humans. Nat Genet 1999; 22:125.</a></li><li><a class="nounderline abstract_t">Hauffa BP, Miller WL, Grumbach MM, et al. Congenital adrenal hyperplasia due to deficient cholesterol side-chain cleavage activity (20, 22-desmolase) in a patient treated for 18 years. Clin Endocrinol (Oxf) 1985; 23:481.</a></li><li><a class="nounderline abstract_t">Nakae J, Tajima T, Sugawara T, et al. Analysis of the steroidogenic acute regulatory protein (StAR) gene in Japanese patients with congenital lipoid adrenal hyperplasia. Hum Mol Genet 1997; 6:571.</a></li><li><a class="nounderline abstract_t">Khoury K, Barbar E, Ainmelk Y, et al. Gonadal function, first cases of pregnancy, and child delivery in a woman with lipoid congenital adrenal hyperplasia. J Clin Endocrinol Metab 2009; 94:1333.</a></li><li><a class="nounderline abstract_t">Hiort O, Holterhus PM, Werner R, et al. Homozygous disruption of P450 side-chain cleavage (CYP11A1) is associated with prematurity, complete 46,XY sex reversal, and severe adrenal failure. J Clin Endocrinol Metab 2005; 90:538.</a></li><li><a class="nounderline abstract_t">Guran T, Buonocore F, Saka N, et al. Rare Causes of Primary Adrenal Insufficiency: Genetic and Clinical Characterization of a Large Nationwide Cohort. J Clin Endocrinol Metab 2016; 101:284.</a></li><li><a class="nounderline abstract_t">Katsumata N, Ohtake M, Hojo T, et al. Compound heterozygous mutations in the cholesterol side-chain cleavage enzyme gene (CYP11A) cause congenital adrenal insufficiency in humans. J Clin Endocrinol Metab 2002; 87:3808.</a></li><li><a class="nounderline abstract_t">Maharaj A, Buonocore F, Meimaridou E, et al. Predicted Benign and Synonymous Variants in CYP11A1 Cause Primary Adrenal Insufficiency Through Missplicing. J Endocr Soc 2019; 3:201.</a></li></ol></div><div id="topicVersionRevision">Topic 15686 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10857554" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Congenital adrenal hyperplasia due to 21-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2026124" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : 17 alpha-hydroxylase/17,20-lyase deficiency: from clinical investigation to molecular definition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4288776" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : 17-hydroxylation deficiency in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8070426" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Disorders of steroid 17 alpha-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14715827" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Two prevalent CYP17 mutations and genotype-phenotype correlations in 24 Brazilian patients with 17-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9326943" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The genetic and functional basis of isolated 17,20-lyase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14504283" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : CYP17 mutation E305G causes isolated 17,20-lyase deficiency by selectively altering substrate binding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3025870" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Cytochrome P450c17 (steroid 17 alpha-hydroxylase/17,20 lyase): cloning of human adrenal and testis cDNAs indicates the same gene is expressed in both tissues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2164530" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Characterization of adrenocorticotropin secretion in a patient with 17 alpha-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/999330" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Female phenotype in a male child due to 17-alpha-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9452426" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Cytochrome b5 augments the 17,20-lyase activity of human P450c17 without direct electron transfer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7045152" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The unique patterns of plasma aldosterone and 18-hydroxycorticosterone concentrations in the 17 alpha-hydroxylase deficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6332824" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Plasma and urinary 19-nor-deoxycorticosterone in 17 alpha-hydroxylase deficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15866602" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Isolated 17,20-lyase (desmolase) deficiency in a 46,XX female presenting with delayed puberty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26862015" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Steroid 17-hydroxylase and 17,20-lyase deficiencies, genetic and pharmacologic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26862015" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Steroid 17-hydroxylase and 17,20-lyase deficiencies, genetic and pharmacologic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29595516" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A Rare Cause of Congenital Adrenal Hyperplasia: Clinical and Genetic Findings and Follow-up Characteristics of Six Patients with 17-Hydroxylase Deficiency Including Two Novel Mutations</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/226795" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Mechanisms establishing the mineralocorticoid hormone patterns in the 17 alpha-hydroxylase deficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6086702" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Diagnosis and natural history of 17-hydroxylase deficiency in a newborn male.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6300176" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : An autopsy case of 17 alpha-hydroxylase deficiency with malignant hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8481334" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Diagnosis and treatment of 17-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18299473" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Metabolic evidence for impaired 17alpha-hydroxylase activity in a kindred bearing the E305G mutation for isolate 17,20-lyase activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14671162" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : P450c17 deficiency in Brazilian patients: biochemical diagnosis through progesterone levels confirmed by CYP17 genotyping.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14758361" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18559916" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Homozygous mutation G539R in the gene for P450 oxidoreductase in a family previously diagnosed as having 17,20-lyase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15220035" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16608896" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Urine steroid hormone profile analysis in cytochrome P450 oxidoreductase deficiency: implication for the backdoor pathway to dihydrotestosterone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2493025" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Combined 17-hydroxylase and 17,20-desmolase deficiencies: evidence for synthesis of a defective cytochrome P450c17.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2855412" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Heterozygotes for 17 alpha-hydroxylase deficiency can be detected with a short ACTH test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6300162" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : 17 alpha-hydroxylase deficiency: mineralocorticoid hormone profiles in an affected family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1863359" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Regional mapping of genes encoding human steroidogenic enzymes: P450scc to 15q23-q24, adrenodoxin to 11q22; adrenodoxin reductase to 17q24-q25; and P450c17 to 10q24-q25.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2843762" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Structural characterization of normal and mutant human steroid 17 alpha-hydroxylase genes: molecular basis of one example of combined 17 alpha-hydroxylase/17,20 lyase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2335573" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Combined 17 alpha-hydroxylase/17,20-lyase deficiency due to a 7-basepair duplication in the N-terminal region of the cytochrome P45017 alpha (CYP17) gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2808364" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Deletion of a phenylalanine in the N-terminal region of human cytochrome P-450(17 alpha) results in partial combined 17 alpha-hydroxylase/17,20-lyase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8345056" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Deletion of amino acids Asp487-Ser488-Phe489 in human cytochrome P450c17 causes severe 17 alpha-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1665206" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Deletion within the CYP17 gene together with insertion of foreign DNA is the cause of combined complete 17 alpha-hydroxylase/17,20-lyase deficiency in an Italian patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8287576" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Combined 17 alpha-hydroxylase/17,20-lyase deficiency caused by heterozygous stop codons in the cytochrome P450 17 alpha-hydroxylase gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3263289" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Combined 17 alpha-hydroxylase/17,20-lyase deficiency due to a stop codon in the N-terminal region of 17 alpha-hydroxylase cytochrome P-450.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8504753" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Steroid 17 alpha-hydroxylase and 17,20-lyase activities of P450c17: contributions of serine106 and P450 reductase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8245018" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Mutation of histidine 373 to leucine in cytochrome P450c17 causes 17 alpha-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14715826" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Two intronic mutations cause 17-hydroxylase deficiency by disrupting splice acceptor sites: direct demonstration of aberrant splicing and absent enzyme activity by expression of the entire CYP17 gene in HEK-293 cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1515452" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Molecular basis of apparent isolated 17,20-lyase deficiency: compound heterozygous mutations in the C-terminal region (Arg(496)----Cys, Gln(461)----Stop) actually cause combined 17 alpha-hydroxylase/17,20-lyase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9177409" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A 5'-splice site mutation in the cytochrome P450 steroid 17alpha-hydroxylase gene in 17alpha-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3951505" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Congenital methemoglobinemia with a deficiency of cytochrome b5.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8168836" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : A splicing mutation in the cytochrome b5 gene from a patient with congenital methemoglobinemia and pseudohermaphrodism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16569739" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : A novel point mutation in P450c17 (CYP17) causing combined 17alpha-hydroxylase/17,20-lyase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16849412" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Two novel mutations found in a patient with 17alpha-hydroxylase enzyme deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18996963" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Puberty in a case with novel 17-hydroxylase mutation and the putative role of estrogen in development of pubic hair.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28225307" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : 17α-HYDROXYLASE/17, 20-LYASE DEFICIENCY: CLINICAL AND MOLECULAR CHARACTERIZATION OF EIGHT CHINESE PATIENTS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8396144" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Expression and purification of functional human 17 alpha-hydroxylase/17,20-lyase (P450c17) in Escherichia coli. Use of this system for study of a novel form of combined 17 alpha-hydroxylase/17,20-lyase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11549685" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Pitfalls in characterizing P450c17 mutations associated with isolated 17,20-lyase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9892022" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : P450c17 mutations R347H and R358Q selectively disrupt 17,20-lyase activity by disrupting interactions with P450 oxidoreductase and cytochrome b5.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/218415" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : 17 alpha-Hydroxylase deficiency. A combination of hydroxylation defect and reversible blockade in aldosterone biosynthesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26647153" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Successful Live Birth in a Woman With 17α-Hydroxylase Deficiency Through IVF Frozen-Thawed Embryo Transfer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13968789" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The adrenogenital syndrome with deficiency of 3 beta-hydroxysteroid dehydrogenase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10599696" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : New insight into the molecular basis of 3beta-hydroxysteroid dehydrogenase deficiency: identification of eight mutations in the HSD3B2 gene eleven patients from seven new families and comparison of the functional properties of twenty-five mutant enzymes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2243100" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Characterization of human 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase gene and its expression in mammalian cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12050224" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Newly proposed hormonal criteria via genotypic proof for type II 3beta-hydroxysteroid dehydrogenase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15585552" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Refining hormonal diagnosis of type II 3beta-hydroxysteroid dehydrogenase deficiency in patients with premature pubarche and hirsutism based on HSD3B2 genotyping.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7626445" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Molecular basis of human 3 beta-hydroxysteroid dehydrogenase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1944309" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Structure and expression of a new complementary DNA encoding the almost exclusive 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase in human adrenals and gonads.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1363812" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Congenital adrenal hyperplasia due to point mutations in the type II 3 beta-hydroxysteroid dehydrogenase gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8004103" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Congenital adrenal hyperplasia caused by a novel homozygous frameshift mutation 273 delta AA in type II 3 beta-hydroxysteroid dehydrogenase gene (HSD3B2) in three male patients of Afghan/Pakistani origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7893703" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Identification and characterization of the G15D mutation found in a male patient with 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) deficiency: alteration of the putative NAD-binding domain of type II 3 beta-HSD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8316254" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Molecular basis of congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7962268" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Molecular basis of congenital adrenal hyperplasia in two siblings with classical nonsalt-losing 3 beta-hydroxysteroid dehydrogenase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8126127" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Detection and functional characterization of the novel missense mutation Y254D in type II 3 beta-hydroxysteroid dehydrogenase (3 beta HSD) gene of a female patient with nonsalt-losing 3 beta HSD deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3160950" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Elevated 17-hydroxyprogesterone and testosterone in a newborn with 3-beta-hydroxysteroid dehydrogenase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13968788" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : The adrenogenital syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31950145" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Revisiting Classical 3β-hydroxysteroid Dehydrogenase 2 Deficiency: Lessons from 31 Pediatric Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2982896" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Late-onset adrenal steroid 3 beta-hydroxysteroid dehydrogenase deficiency. I. A cause of hirsutism in pubertal and postpubertal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8456898" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : 3 beta-hydroxysteroid dehydrogenase deficiency in hyperandrogenism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12608938" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Carriers for type II 3beta-hydroxysteroid dehydrogenase (HSD3B2) deficiency can only be identified by HSD3B2 genotype study and not by hormone test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14764821" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Molecular study of the 3 beta-hydroxysteroid dehydrogenase gene type II in patients with hypospadias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6300166" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Nonsalt-losing congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency with normal glomerulosa function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6249838" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Pubertal presentation of congenital delta 5-3 beta-hydroxysteroid dehydrogenase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10651755" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Mutations in the type II 3beta-hydroxysteroid dehydrogenase (HSD3B2) gene can cause premature pubarche in girls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7988480" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Disorders of steroid 11 beta-hydroxylase isozymes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1554023" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : High frequency of congenital adrenal hyperplasia (classic 11 beta-hydroxylase deficiency) among Jews from Morocco.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2022736" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : A mutation in CYP11B1 (Arg-448----His) associated with steroid 11 beta-hydroxylase deficiency in Jews of Moroccan origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6296182" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Clinical and biochemical variability of congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency. A study of 25 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2984117" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Partial deficiency of adrenal 11-hydroxylase. A possible cause of primary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7049883" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Clinical variability of congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12966519" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Mutations in CYP11B1 gene: phenotype-genotype correlations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3011843" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Requirement of mineralocorticoid in congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6607265" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Salt loss in hypertensive form of congenital adrenal hyperplasia (11-beta-hydroxylase deficiency).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6966049" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Neonatal salt loss in the hypertensive form of congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12876421" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Hyperplasia of adrenal rest tissue causing a retroperitoneal mass in a child with 11 beta-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12602540" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Bilateral testicular enlargement due to adrenal remnant in a patient with C11 hydroxylase deficiency congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6249834" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Adrenocortical 11 beta-hydroxylation defect in adult women with postmenarchial onset of symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3007557" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Adrenal androgen hyperresponsiveness to adrenocorticotropin in women with acne and/or hirsutism: adrenal enzyme defects and exaggerated adrenarche.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9302260" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : CYP11B1 mutations causing non-classic adrenal hyperplasia due to 11 beta-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23940125" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : A diagnosis not to be missed: nonclassic steroid 11β-hydroxylase deficiency presenting with premature adrenarche and hirsutism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33830237" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Clinical and Hormonal Profiles Correlate With Molecular Characteristics in Patients With 11β-Hydroxylase Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13851523" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Urinary steroids in the hypertensive form of congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1334496" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Normative data for the steroidogenic response of mineralocorticoids and their precursors to adrenocorticotropin in a healthy pediatric population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1651957" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Normative data for adrenal steroidogenesis in a healthy pediatric population: age- and sex-related changes after adrenocorticotropin stimulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13513739" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Urinary corticosteroid excretion patterns in patients with adrenocortical dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14289500" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : ADRENOCORTICAL 11-BETA-HYDROXYLASE DEFICIENCY AND VIRILISM FIRST MANIFEST IN THE ADULT WOMEN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25536973" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : The classic and nonclassic concenital adrenal hyperplasias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6244328" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Hormonal studies in obligate heterozygotes and siblings of patients with 11 beta-hydroxylase deficiency congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8506298" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Mutations in the CYP11B1 gene causing congenital adrenal hyperplasia and hypertension cluster in exons 6, 7, and 8.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16046588" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : 21-Hydroxylase and 11beta-hydroxylase mutations in Romanian patients with classic congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15755848" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Congenital adrenal hyperplasia due to 11-hydroxylase deficiency: functional characterization of two novel point mutations and a three-base pair deletion in the CYP11B1 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1430088" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Frame shift by insertion of 2 basepairs in codon 394 of CYP11B1 causes congenital adrenal hyperplasia due to steroid 11 beta-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7903314" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : A nonsense mutation (TGG [Trp116]--&gt;TAG [Stop]) in CYP11B1 causes steroid 11 beta-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14682466" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : A novel nonsense mutation in the Cyp11B1 gene from a subject with the steroid 11beta-hydroxylase form of congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11443188" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Deletion hybrid genes, due to unequal crossing over between CYP11B1 (11beta-hydroxylase) and CYP11B2(aldosterone synthase) cause steroid 11beta-hydroxylase deficiency and congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11549691" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Unequal crossing-over between aldosterone synthase and 11beta-hydroxylase genes causes congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17726333" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Successful pregnancy in a patient with severe 11-beta-hydroxylase deficiency and novel mutations in CYP11B1 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/314453" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Prenatal diagnosis of 11beta-hydroxylase deficiency congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10487675" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Prenatal diagnosis and treatment of 11beta-hydroxylase deficiency congenital adrenal hyperplasia resulting in normal female genitalia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2932643" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Male pseudohermaphroditism due to multiple defects in steroid-biosynthetic microsomal mixed-function oxidases. A new variant of congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15216541" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Biochemical diagnosis of Antley-Bixler syndrome by steroid analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15491389" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Abnormal steroidogenesis in three patients with Antley-Bixler syndrome: apparent decreased activity of 17alpha-hydroxylase, 17,20-lyase and 21-hydroxylase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19258400" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Cytochrome P450 oxidoreductase deficiency: identification and characterization of biallelic mutations and genotype-phenotype correlations in 35 Japanese patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15793702" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16906539" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Linking Antley-Bixler syndrome and congenital adrenal hyperplasia: a novel case of P450 oxidoreductase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15666853" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : A male twin infant with skull deformity and elevated neonatal 17-hydroxyprogesterone: a prismatic case of P450 oxidoreductase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16439592" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1227559" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Trapezoidocephaly, midfacial hypoplasia and cartilage abnormalities with multiple synostoses and skeletal fractures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17505056" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Differential inhibition of CYP17A1 and CYP21A2 activities by the P450 oxidoreductase mutant A287P.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17595315" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Modulation of human CYP19A1 activity by mutant NADPH P450 oxidoreductase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15483095" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Cytochrome P450 oxidoreductase gene mutations and Antley-Bixler syndrome with abnormal genitalia and/or impaired steroidogenesis: molecular and clinical studies in 10 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12116245" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Abnormal sterol metabolism in a patient with Antley-Bixler syndrome and ambiguous genitalia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15189162" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Novel lipid modifications of secreted protein signals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9332650" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Multiple malformation syndrome following fluconazole use in pregnancy: report of an additional patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8838193" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Fluconazole-induced congenital anomalies in three infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19264869" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : P450 oxidoreductase expressed in rat chondrocytes modulates chondrogenesis via cholesterol- and Indian Hedgehog-dependent mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18551037" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17827787" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Novel SNPs in cytochrome P450 oxidoreductase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18433346" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : P450 oxidoreductase: genetic polymorphisms and implications for drug metabolism and toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18216718" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Genetic polymorphisms in cytochrome P450 oxidoreductase influence microsomal P450-catalyzed drug metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18230729" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18455494" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Impairment of human CYP1A2-mediated xenobiotic metabolism by Antley-Bixler syndrome variants of cytochrome P450 oxidoreductase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15266606" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Undetectable maternal serum uE3 and postnatal abnormal sterol and steroid metabolism in Antley-Bixler syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15316970" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Prenatal diagnosis of P450 oxidoreductase deficiency (ORD): a disorder causing low pregnancy estriol, maternal and fetal virilization, and the Antley-Bixler syndrome phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9605588" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : FGFR2 mutation associated with clinical manifestations consistent with Antley-Bixler syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10633130" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Evidence for digenic inheritance in some cases of Antley-Bixler syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11430730" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Further evidence that fibroblast growth factor receptor 2 mutations cause Antley-Bixler syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16470797" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : POR R457H is a global founder mutation causing Antley-Bixler syndrome with autosomal recessive trait.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14625002" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Apparent pregnene hydroxylation deficiency (APHD): seeking the parentage of an orphan metabolome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15466942" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : 11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11150889" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Apparent cortisone reductase deficiency: a rare cause of hyperandrogenemia and hypercortisolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12858176" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Mutations in the genes encoding 11beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10522997" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Apparent cortisone reductase deficiency: a functional defect in 11beta-hydroxysteroid dehydrogenase type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18628520" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Steroid biomarkers and genetic studies reveal inactivating mutations in hexose-6-phosphate dehydrogenase in patients with cortisone reductase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12649576" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : 11beta-hydroxysteroid dehydrogenase type 1 deficiency ('apparent cortisone reductase deficiency') in a 6-year-old boy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8370690" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Defects in the HSD11 gene encoding 11 beta-hydroxysteroid dehydrogenase are not found in patients with apparent mineralocorticoid excess or 11-oxoreductase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8923828" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Apparent cortisone reductase deficiency: a unique form of hypercortisolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10349511" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Human hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase) encoded at 1p36: coding sequence and expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16817821" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Variants implicated in cortisone reductase deficiency do not contribute to susceptibility to common forms of polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17062770" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Lack of Association of the 11beta-hydroxysteroid dehydrogenase type 1 gene 83,557insA and hexose-6-phosphate dehydrogenase gene R453Q polymorphisms with body composition, adrenal androgen production, blood pressure, glucose metabolism, and dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9771708" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Mutations in orthologous genes in human spondyloepimetaphyseal dysplasia and the brachymorphic mouse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19474428" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Inactivating PAPSS2 mutations in a patient with premature pubarche.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25594860" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : PAPSS2 deficiency causes androgen excess via impaired DHEA sulfation--in vitro and in vivo studies in a family harboring two novel PAPSS2 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12372849" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Sulfonation and molecular action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9714015" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Distinct, autosomal recessive form of spondyloepimetaphyseal dysplasia segregating in an inbred Pakistani kindred.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7761400" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Human steroidogenic acute regulatory protein: functional activity in COS-1 cells, tissue-specific expression, and mapping of the structural gene to 8p11.2 and a pseudogene to chromosome 13.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7892608" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Role of steroidogenic acute regulatory protein in adrenal and gonadal steroidogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7961770" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : The purification, cloning, and expression of a novel luteinizing hormone-induced mitochondrial protein in MA-10 mouse Leydig tumor cells. Characterization of the steroidogenic acute regulatory protein (StAR).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8382603" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : The use of genetic manipulation of MA-10 Leydig tumor cells to demonstrate the role of mitochondrial proteins in the acute regulation of steroidogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1918079" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : The 30-kDa mitochondrial proteins induced by hormone stimulation in MA-10 mouse Leydig tumor cells are processed from larger precursors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8948562" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : The pathophysiology and genetics of congenital lipoid adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10566637" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : A novel compound heterozygous mutation in the steroidogenic acute regulatory protein gene in a patient with congenital lipoid adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14764819" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Congenital lipoid adrenal hyperplasia caused by a novel splicing mutation in the gene for the steroidogenic acute regulatory protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12943739" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Molecular pathogenesis of lipoid adrenal hyperplasia and adrenal hypoplasia congenita.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26960203" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Disorders in the initial steps of steroid hormone synthesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9141542" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Spontaneous feminization in a 46,XX female patient with congenital lipoid adrenal hyperplasia due to a homozygous frameshift mutation in the steroidogenic acute regulatory protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16968793" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Nonclassic congenital lipoid adrenal hyperplasia: a new disorder of the steroidogenic acute regulatory protein with very late presentation and normal male genitalia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20444910" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : Clinical, genetic, and functional characterization of four patients carrying partial loss-of-function mutations in the steroidogenic acute regulatory protein (StAR).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15289763" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : Near-miss apparent SIDS from adrenal crisis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9077535" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : Spontaneous puberty in 46,XX subjects with congenital lipoid adrenal hyperplasia. Ovarian steroidogenesis is spared to some extent despite inactivating mutations in the steroidogenic acute regulatory protein (StAR) gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11502818" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : Heterozygous mutation in the cholesterol side chain cleavage enzyme (p450scc) gene in a patient with 46,XY sex reversal and adrenal insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10369247" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : A mutation in the gene encoding steroidogenic factor-1 causes XY sex reversal and adrenal failure in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3841304" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : Congenital adrenal hyperplasia due to deficient cholesterol side-chain cleavage activity (20, 22-desmolase) in a patient treated for 18 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9097960" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : Analysis of the steroidogenic acute regulatory protein (StAR) gene in Japanese patients with congenital lipoid adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19158201" id="rid177" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>178 : Gonadal function, first cases of pregnancy, and child delivery in a woman with lipoid congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15507506" id="rid178" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>179 : Homozygous disruption of P450 side-chain cleavage (CYP11A1) is associated with prematurity, complete 46,XY sex reversal, and severe adrenal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26523528" id="rid179" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>180 : Rare Causes of Primary Adrenal Insufficiency: Genetic and Clinical Characterization of a Large Nationwide Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12161514" id="rid180" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>181 : Compound heterozygous mutations in the cholesterol side-chain cleavage enzyme gene (CYP11A) cause congenital adrenal insufficiency in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30620006" id="rid181" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>182 : Predicted Benign and Synonymous Variants in CYP11A1 Cause Primary Adrenal Insufficiency Through Missplicing.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
